Decision Partner Involvement in Cancer Clinical Trial Participation by Gray, Tamryn F
 
 









A dissertation submitted to Johns Hopkins University in conformity with the requirements for 












© 2018 Tamryn F. Gray 











 Clinical trials help to advance scientific knowledge and provide novel therapies to 
patients, yet only 3-5% of adults with cancer participate in clinical trials. Gaps remain in our 
understanding about the role of decision partners in clinical trial decision making, which may be 
critical to clinical trial recruitment and retention. Decision partners are family and friends who 
are engaged in health care decision making. The purpose of this exploratory, descriptive 
dissertation was to examine relationships between individual patient factors, decision control 
preferences for decision partner involvement, and clinical trial participation (CTP). This mixed 
methods study included quantitative analysis of ongoing data from a parent study and a 
qualitative study. The two study aims were to: describe the relationships between patient factors, 
decision control preferences for decision partner involvement, clinical trial knowledge, attitudes, 
and beliefs (CTKAB), and CTP; and explore the process of decision making about CTP among 
persons with varying decision control preferences. Quantitative results (n=82) showed that there 
are some associations between CTP, CTKAB, and patient factors, though none of our findings 
were found to be statistically significant at p-value < 0.05. This may possibly be due to the small 
number of participants who were actually offered a clinical trial (25%, n=21), leaving most 
participants unable to make a clinical trial decision. The qualitative study with patients and 
decision partners (n=24) provided insight into clinical trial decision-making among those with 
varying decision control preferences. Four themes emerged: Having the freedom to choose, 
Getting the most insight about clinical trials, Building relationships...trusting someone in the 
process, and Realizing readiness and context. In conclusion, providers still have an important 
influence in clinical trial decision making, but decision partners are often engaged at varying 





diverse populations and over time, address barriers to clinical trial eligibility, examine 
relationships between providers and decision partners, and incorporate stated-preference 
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CHAPTER I: Introduction and Background 
Introduction 
Cancer is a major health concern and the second leading cause of death in the United 
States, second to heart disease (Salman, Nguyen, Lee, & Cooksey-James, 2016). Shortly after a 
cancer diagnosis, patients must make difficult treatment decisions, which may include a decision 
about participating in cancer clinical trials, given that some patients may and may not be eligible 
or offered clinical trials until later in their treatment trajectory.  Clinical trials are research studies 
that helps pave the way for new treatments, protocols, and interventions to see if these new 
therapies are safe and effective in people. Clinical trials offer patients the opportunity to be 
treated using an investigational drug rather than standard treatment or enrolling in a different 
treatment protocol that may include a combination of different therapies. Participation in clinical 
trials is essential in cancer care to improve the overall care and well-being of this patient 
population, yet less than 5% of adults with cancer choose this option. Low accrual into clinical 
trials compromises the success of clinical trials, wastes valuable resources, and squanders an 
opportunity for improving patient outcomes (Bell & Balneaves, 2015).  
Notably, any investigational drug has risks and benefits, including whether it is effective 
in treating the individual’s cancer or causes harm. It is important to understand the barriers to 
participating in clinical trials experienced by cancer patients, as well as the personal, social, 
structural, and political contexts that impinge on patients’ abilities to take part in clinical 
research (Bell & Balneaves, 2015). Although patients have individual autonomy in clinical trial 
decision making, given the complexity and risks involved, some patients may prefer to share 
decision control with decision partners. Decision partners are defined as family and friends who 





decision regret in clinical trial decision-making (Wenzel, Mbah, Xu, Moscou-Jackson, Saleem, 
Sakyi, & Ford, 2015). 
Background and Rationale 
Significant gaps remain in our understanding of how patients decide to participate in 
research and who or what might be important in the decisional process. Patients often want to 
involve decision partners to navigate complex decisions. Understanding cancer patients’ 
preferences for decisional roles is important in providing quality cancer care and ensuring patient 
satisfaction (Yennurajalingam, Parsons, Duarte, Palma, Bunge, Palmer, Delgado-Guay, Allo, & 
Bruera, 2013). Understanding these relationships is critical if we want to improve the clinical 
trial recruitment and retention, and it is important for clinicians and researchers to pay attention 
to the different relationship dynamics that patients have when promoting shared decision making 
(Symes et al., 2015).  
Review of the Literature 
Search Strategy.  With the aid of a librarian, a comprehensive search was undertaken in 
EMBASE, CINAHL, and PubMed databases to identify English-language studies published 
between 2006 and 2017, with notable articles published as early as 1989. These original research 
articles addressed cancer patient populations, family research, motivating factors and barriers to 
clinical trial participation, and family involvement in treatment decision-making. The database 
search included the following keywords and MeSH terms: “decision making, family", "decision 
making", "decision-making", "decision making, patient", “collaborative OR shared”, "decision 
making", "patient participation", “family”, "clinical trials", "clinical trial", “neoplasms” 





Review of the Literature of Cancer Clinical Trial Participation. Clinical trials have 
produced prevention, treatment, and outcome advances, and nowhere has this been more evident 
than in cancer (Wang, Tsai, Chen, & Tsay, 2011; Barakat, Schwartz, Reilly, Deatrick, & Balis, 
2014). Cancer clinical trials are necessary for the improvement of patient care as they have the 
ability to demonstrate the efficacy and safety of novel cancer treatments (Bell & Balneaves, 
2015). Despite its role in advances, clinical trial participation among adults with cancer remains 
as low as 3-5%, with minority groups greatly underrepresented (Wang, Tsai, Chen, & Tsay, 
2011; Brown, Cadet, Houlihan, Thomson, Pratt, Sullivan, & Siminoff, 2013; Buss, DuBenske, 
Dinauer, Gustafson, McTavish, & Cleary, 2008). Low participation rates have critically delayed 
scientific progress to derive treatments to fight cancer and reduce cancer health disparities 
(Brown et al., 2013; Albrecht, Eggly, Gleason, Harper, Foster, Peterson, Orom, Penner, & 
Ruckdeschel, 2008).  In a recent analysis of trial accrual performance among adult oncology 
studies in the US, Cheng et al. reported 81.5% of trials did not achieve accrual goals within the 
anticipated accrual period (Bell & Balneaves, 2015; Cheng, Dietrich, & Dilts, 2011).  Though we 
understand some barriers to clinical trial participation (Unger, Cook, Tai, & Bleyer, 2016; Lee, 
Ow, Lie, & Dent, 2016), there is a clear urgency to understand the decision-making process that 
influence enrollment.   
Cancer research has become a national priority and requires the need for patients to 
participate in clinical trials (Altshuler, 2016). Yet, there are unknown benefits and risks 
associated with participation. Patients cannot predict whether the new treatments and 
interventions in clinical trials will improve or worsen their health outcomes. Additionally, 
clinical trials are often introduced early in treatment, when emotionality is intense, relationships 





Kim-Sing, & Hislop, 2013).  Hence, making decisions about clinical trial participation can often 
occur when patients are particularly vulnerable (Thorne et al., 2013; Rutten, Arora, Bakos, Aziz, 
& Rowland, 2005), taking additional physical and mental energy (Butow, Maclean, Dunn, 
Tattersall, & Boyer, 1997).   
Review of the Literature of Role of Family and Friends.  Decision-making about 
clinical trial participation is not often clear and straightforward. There are potential risks and 
benefits to consider beforehand. Many patients may depend on decision partners to get through 
the process. Extensive research has shown that a patient’s family and friends play an integral role 
in patient decision choices about treatment (Hubbard, Kidd, & Donaghy, 2008; Lin, Pang, & 
Chen, 2013; Quinn, McIntyre, Gonzalez, Antonia, Antolino, & Wells, 2013; Laidsaar-Powell, 
Butow, Bu, Charles, Gafni, Fisher, & Juraskova, 2016; Shin, Cho, Roter, Kim, Sohn, Yoon, 
Kim, Cho, & Park, 2013).  Whether or not family members are present, clinicians must 
conceptualize cancer care as a family issue because family members are often consulted by 
patients before medical visits and discuss their care and treatment options (Sharma, Hughes, 
Nolan, Tudor, Kub, Terry, & Sulmasy, 2011; Laidsaar-Powell et al., 2016).  Family members 
and friends are not only the providers of social support, but also are the key participants in 
treatment decision-making (Shin et al., 2013; Lingler, Sherwood, Crighton, Song, & Happ, 
2008).  
Furthermore, research evidence suggests that the majority of patients prefer shared 
decision-making (Wei et al., 2016), and Quantitative studies show that a majority of cancer 
patients (49–84%) and family members (54–59%) prefer family participation in decision-making 
to some extent (Laidsaar-Powell et al., 2016; Pardon et al., 2010; Shin et al., 2013). In some 





opinions in the larger community may be an important first step before patient recruitment (Lee, 
Ow, Lie, & Dent, 2016). From an ethical standpoint, respect for autonomy requires physicians to 
take into a patient’s preferences regarding medical decision-making, including the preference to 
involve the family (Pardon et al., 2010), and that the preferences in which patients have for 
involving families and friends should be viewed within the context of personal values and 
culture, such as familial obligation and loyalty (Clayman, Roter, Wissow, & Bandeen-Roche, 
2005).  
Review of the Literature of Other Influential Factors.  There are multiple factors that 
may impact participation in clinical trials, including attitudinal, structural, and clinical barriers, 
physician and patient attitudes, and sociocultural factors (Unger, Cook, Tai, & Bleyer, 2016; 
Lee, Ow, Lie, & Dent, 2016).  Patients’ attitudes toward living with cancer affect whether they 
can decide to accept or decline participation (Kohara & Inoue, 2010). A conservative attitude 
towards risk-taking can be a barrier for patients and prevent them from participating in a clinical 
trial (Lee, Ow, Lie, & Dent, 2016). Patients may be unwilling to join a clinical trial if they 
perceive a worse risk-benefit ratio to joining as there may be unanticipated side effects combined 
with a perceived lack of efficacy data on the investigational drug (Lee, Ow, Lie, & Dent, 2016). 
Clinical and physician barriers may include clinical trial ineligibility, physicians may have a 
strong inclination toward a specific treatment for a given patient, physicians may also anticipate 
that the introduction of uncertainty about a clinical trial outcome will subvert patient confidence 
in their expertise, and fear that clinical trials will be too time-consuming (Unger, Cook, Tai, & 
Bleyer, 2016). Some facilitators to enrollment include late stage disease, sense of altruism 
(Truong, Weeks, Cook, & Joffe, 2011), trust in physicians, and prior positive experience with 





Gaps in the Literature. Patients’ preferences for involving decision partners in decision-
making may also be affected by the nature of the illness and the patient’s relationship with the 
clinician and decision partner. Although it is known that families and friends are often engaged 
in cancer care and treatment, there is a knowledge gap in understanding the way in which those 
relationships, specifically with decision partners, influence the patient’s own decision-making 
about clinical trial participation. The degree to which family members influenced patients’ 
choices for the patients’ own good (versus the family’s good), how they were involved in the 
decision-making process, and patients’ preferences with regard to the involvement of their 
family in clinical trial decisions remain largely unexplored (Bell & Balneaves, 2015). Research 
informed by the theoretical lens of relational autonomy is required to explore how cancer 
patients reach the decision to engage in a clinical trial both as an individual and as a social being 
embedded in relationships (Bell & Balneaves, 2015). Hence, there is a need to examine the 
relationships between individual patient factors, decision control preferences for decision partner 
involvement, and clinical trial participation.  
Purpose of Dissertation Research  
The purpose of the dissertation is to examine the relationships between individual patient 
factors, decisional control preferences for decision partner involvement, and clinical trial 
participation. 
Specific Aims/Hypotheses 
The specific aims and hypotheses of this dissertation were:  
AIM 1: To describe the relationships between Patient Factors (Decision Control 
Preferences, Age, Gender, Education, Marital Status, Race, Ethnicity), Clinical Trial 





Hypothesis 1.1: Individual patient factors are associated with clinical trial participation. Lower 
educational attainment will be associated with decreased participation in a clinical trial.  
Younger age will be positively associated with clinical trial participation.  
Hypothesis 1.2: Knowledge, attitudes and beliefs will be associated with clinical trial 
participation. An increased clinical trial knowledge level and more positive attitudes and beliefs 
about clinical trials will be positively associated with a patient’s decision to participate in a 
clinical trial.   
Hypothesis 1.3: Educational attainment will be associated with decision control preference. 
Higher education attainment will be associated with a higher level of decisional control 
preference.  
Hypothesis 1.4 Decision control preferences will be associated with clinical trial participation.  
Preferences for a more deferred decision style will be positively associated with patient’s 
decision to participate in a clinical trial. 
AIM 2: To explore the process of decision making about clinical trial participation among 
persons with high levels of decisional control preferences and those with a more deferred 
decision style.   
 
Significance of Research  
When making decisions about clinical trials, it is crucial to understand patients’ decision 
control preferences for involving decision partners in decisions about clinical trial participation. 
In an era of increasing emphasis on shared treatment decision-making and on the principle of 
relationality, the opportunity for patients to identify how they prefer the involvement of decision 





(Unger, Cook, Tai, & Bleyer, 2016), especially when research has shown that cancer decisions 
are not so simple (Reyna, Nelson, Han, & Pignone, 2015).  A patient’s decision about which 
cancer treatment to receive is complex and deeply personal (Unger, Cook, Tai, & Bleyer, 2016).  
Patients may want to expand the concept of shared decision making from patient-provider to also 
involve decision partners. The role of decision partners is worth examining because their 
involvement could potentially aid or impede decision-making about clinical trial participation.  
Our research findings have the potential to guide interventions that may improve clinical trial 
recruitment and retention for the advancement of cancer care.  
Dissertation Organization 
 This dissertation is organized into 5 chapters. This first chapter introduces the need for 
the study by providing background, rationale and significance of the research followed by the 
specific aims. The second chapter describes the methodology of the dissertation study, including 
detail about the parent study schema. The third chapter (manuscript one) reviews the concept of 
decision partner and synthesize evidence from published studies that employ it in an effort to 
better understand its definition, attributes, and usefulness in the areas of patient and family health 
care decision making.  The fourth chapter is an examination of the relationship between Patient 
Factors (Decision Control Preferences, Age, Gender, Education, Marital Status, Race, Ethnicity), 
Clinical Trial Knowledge, Attitudes, and Beliefs, and Clinical Trial Participation.  The fifth 
chapter describes the qualitative findings that explored the process of decision making about 
clinical trial participation among persons with high levels of decisional control preferences and 
those with a more deferred decision style.  The sixth chapter summarizes the findings of the 
previous chapters in the context of other family research and describes the potential areas of 





CHAPTER II: Dissertation Methodology 
This dissertation contains a mixed-methods design comprising of a quantitative arm and a 
qualitative arm. This chapter describes detail about the methodology used in the dissertation 
study.   
Conceptual Framework 
This dissertation study addresses a knowledge gap by providing insight into the potential 
ways that patients involve decision partners when making difficult decisions about cancer 
clinical trial participation. The study was guided by a Conceptual Model of Decision Partner 
Engagement in Cancer Clinical Trial Decision-Making, developed from the following two 
models: (1) The Decision Making Ecology (DME) Framework and (2) the Model of Cancer 
Clinical Trial Decision-Making. The DME Framework (Figure 1) was originally developed to 
guide the decision-making for child protective services workers when they make decisions about 
an individual child case (Maguire-Jack & Font, 2014).  It provides a theoretical and testable basis 
for understanding the context, process, and outcomes or consequences of child welfare decision-
making (Fluke, Baumann, Dalgleish, & Kern, 2014). This framework was intended to provide an 
understanding of both the context and process of decision-making and to predict “behavioral 
thresholds for action” (Fluke, Baumann, Dalgleish, & Kern, 2014). Multiple influences for 
decisions are addressed within the framework, including individual patient factors and external 
forces (Baumann, Dalgleish, Fluke, & Kern, 2011). Components of this framework provides an 
overall understanding of the individual and social factors that contribute to patient decision 
choices, including micro- and macro- perspectives (Maguire-Jack & Font, 2014; Kozlowski & 








Model of Cancer Clinical Trial Decision-Making (Figure 2), which includes both inter- and intra-
personal influences surrounding clinical trial decision-making (Wenzel, Mbah, Xu, Moscou-
Jackson, Saleem, Sakyi, & Ford, 2015), has also been incorporated in the overall study 
framework. It was originally developed from data collected among clinical trial-eligible African 
American cancer patients to better understand research decision-making (Wenzel et al., 2015). In 
this study, the researchers found that participants who chose to participate reported the 
importance of support from family and friends and/or spiritual motivation to participate (Wenzel 
et al., 2015). Though originally developed from focus groups with African American adult 
cancer patients, clinicians and researchers have commented on the broader applicability of many 
components, especially the inclusion of decision partners. Thus, the model helped to guide the 





dissertation study, which included a racially/ethnically heterogeneous sample. 
 
Figure 2. The Model of Cancer Clinical Trial Decision-Making (Wenzel et al., 2015) 
 
For the dissertation study, the outcome variable was clinical trial participation (yes, no, 
not offered/delayed offer); the independent variables and covariates were individual patient 
factors (age, race, ethnicity, gender, education level, clinical trial knowledge, attitudes, and 
beliefs, decision control preferences for decision partner involvement), and interpersonal 
decision partner factors. The Conceptual Model of Decision Partner Engagement in Cancer 
Clinical Trial Decision-Making, the theoretical framework for the dissertation, is depicted Figure 
3. The systemic context for decision-making includes a set of decision-making influences 
displayed as ovals, including case-specific factors, external or decision partner factors, and 
individual factors that combine in various ways to influence decisions and outcomes (Fluke, 








Parent Study Design.  The dissertation study was a nested study within the parent study entitled 
EMPaCT Patient Navigation Study.  The objective of this parent study was to increase 
recruitment and retention of racial/ethnic minorities into therapeutic clinical trials through the 
well-established EMPaCT consortium with the ultimate goal of reducing cancer-related health 
disparities.  Specifically, the consortium is a national system that used a coordinated approach 
with five consortium institutions to address accrual into clinical trials on multiple levels. The 
EMPaCT Patient Navigation Study was a randomized trial conducted with the purpose of 






implementing and evaluating a patient navigation program designed to increase recruitment and 
retention of minority patients into therapeutic cancer clinical trials. In this study, community 
patient navigators work with oncology nurses and other clinicians to help patients overcome 
barriers to participation and navigate through the healthcare system. For the parent study, 
participants were randomized to High Intensity Clinical Trial Navigation (Intervention Arm) or 
to Low Intensity Navigation (Control Arm). The target recruitment sample for the parent study 
was 110 participants.  This parent study had ongoing data collection while the dissertation study 
was being conducted.   
 
Figure 4. Parent Study Schema 
Dissertation Study Design.  Study variables were selected from the parent study based on 
relevance to the dissertation study purpose, and address factors relevant to the conceptual model. 
Inclusion and exclusion criteria for this dissertation study were the same as for the parent study. 
The sample size for this dissertation study was 82 individuals. The dissertation study had a cross-





from the parent study. Thus, this study is composed of an analysis of ongoing quantitative patient 
data, including the addition of decision control preference data using a modified version of the 
Control Preferences Scale, decision partner factors, and primary qualitative data collection.  Data 
points that were also collected for decision partners included age, gender, race, and ethnicity.  
The occupation and work experiences of decision partners also emerged as data from the 
interviews. The qualitative interviews followed quantitative data collection. Qualitative 
participants were purposively sampled from respondents of the quantitative arm to participate in 
interviews based on a maximum variation of scored preferences for decision partner involvement 
on the modified Control Preference Scale. This phase involved a smaller number of patient 
participants (n=12) who all had an available clinical trial based on a screening algorithm and 















Figure 5. Dissertation Study Schema 
 
Quantitative Study Methods 
Study Aim 
AIM 1: To describe the relationships between Patient Factors (Decision Control 
Preferences, Age, Gender, Education, Marital Status, Race, Ethnicity), Clinical Trial 
Knowledge, Attitudes, and Beliefs, and Clinical Trial Participation.   





Lower educational attainment will be associated with decreased participation in a clinical trial. 
Younger age will be positively associated with clinical trial participation.  
 
Hypothesis 1.2: Knowledge, attitudes and beliefs will be associated with clinical trial 
participation. An increased clinical trial knowledge level and more positive attitudes and beliefs 
about clinical trials will be positively associated with a patient’s decision to participate in a 
clinical trial.   
 
Hypothesis 1.3: Educational attainment will be associated with decision control preference. 
Higher education attainment will be associated with a higher level of decisional control 
preference.  
 
Hypothesis 1.4 Decision control preferences will be associated with clinical trial participation.  
Preferences for a more deferred decision style will be positively associated with patient’s 
decision to participate in a clinical trial. 
 
Research Variables. 
A list of the major variables and instruments used in the analyses are described below:   
Sociodemographic Factors 
Patients reported their age, gender, highest level of educational attainment, marital status, 
race, and ethnicity as key sociodemographic factors obtained for the study. Sociodemographic 
factors are those modifiable and unmodifiable patient and decision partner characteristics that 





factors are socially constructed and have been shown to be predictors or characteristics of cancer 
patients who participate in clinical trials.  The categories for gender included male and female. 
The categories for race were: African American or Black, White, Asian or Asian American, 
American Indian or Alaska Native, and Native Hawaiian or Pacific Islander, or Other.  The 
categories for ethnicity used in this study were Hispanic or Latino and non-Hispanic or Latino.  
The options for educational attainment included 8th grade or less, 9th-11th grade, high school 
graduate, some college, community college/technical, bachelor’s degree, master’s degree, 
doctoral degree, and missing/unreported. The options for marital status included single, married, 
separated or divorced, widowed, lives with partner, and missing/unreported. Information was 
obtained through electronic medical records and patient self-report.  
Cancer Type 
The cancer type is defined as the primary tumor site of the patient. Generated from our 
study sample, data regarding the specific cancer type was used in analysis. There was a wide 
array of solid tumor cancer diagnoses represented by our study sample, including breast, 
prostate, multiple myeloma, ovarian, head and neck, and endometrial.   
Clinical trial knowledge, attitudes, and beliefs assessment (CTKAB) 
Study participants were asked about their knowledge, attitudes, and beliefs about clinical 
trials using the 18-item Clinical Trial Knowledge, Attitudes, and Beliefs Assessment.  
Participants responded to statements such as “The information gained from clinical trials may 
help a friend or family member”, “I think all patients who are eligible should be asked to take 
part in clinical trials”, “I would only take part in a clinical trial if I thought that my own health 
would benefit”.  The entire assessment can be in found in Appendix E. The survey has been 





investigators of the parent study, for patients to report on a five-point Likert scale that ranged 
from 1(strongly agree) to 5 (strongly disagree). The assessment was reverse coded to have higher 
scores reflect having more knowledge and more positive attitudes and beliefs about clinical 
trials. After the reverse scoring, an additive scale score could range from 18 to 90; high scores 
indicate higher knowledge and more positive attitudes and beliefs about clinical trials. We 
decided to include this questionnaire in our study because research indicates that cancer patients 
who are offered or enrolled may have low levels of knowledge about clinical trials (Cox, 2000) 
or misperceptions about how they function (Curbow, Fogarty, McDonnell, Chill, & Scott, 2004; 
Itoh et al., 1997). In general, research has shown knowledge deficits (Curbow, Fogarty, 
McDonnell, Chill, & Scott, 2004; Ellis & Butow, 1998). Cox (2000) conducted a series of four 
interviews with 55 patients with advanced cancer who were offered participation in Phase I or 
Phase II trials. Results indicated that only 16% of the patients could explain the purpose of the 
clinical trial they were offered. Patients have been shown to decline participation if the 
information about the clinical trial was difficult to understand (Curbow, Fogarty, McDonnell, 
Chill, & Scott, 2004; Lovegrove, Rumsey, Harcourt, & Cawthorn, 2000). Moreover, with 
increasing numbers of studies on research ethics and a need to improve the recruitment of 
research subjects, the ability to measure attitudes toward biomedical research has become 
important (Rubright, Cary, Karlawish, & Kim, 2011).  
Decision Control Preferences 
Decisional control is often used in the decision science literature to describe patients’ 
ability to play an active role in making decisions about their treatment (Ghane, Huynh, Andrews, 
Legg, Tabuenca, & Sweeny, 2014). It refers to patients’ specific role in a treatment decision 





participants’ decision control preferences for decision partner involvement using the Control 
Preferences Scale (CPS).  The original scale has been used and validated in several studies to 
assess the degree of control patients prefer over medical decisions with their doctors (Degner & 
Sloan, 1992).  The question and five response options of the original scale include, “How do you 
prefer to make medical decisions with your doctors?: 1) I make all medical decisions on my own; 
2) I make the final decision myself only after considering my doctor's opinion; 3) My doctors 
and I share decision making equally; 4) My doctors make the final decision for me only after 
considering my opinion; 5) My doctors make all medical decisions for me.” (Degner & Sloan, 
1992; Chiu, Feuz, McMahan, Miao, & Sudore, 2016).  
For our study, we modified the scale to assess decision control preferences that patients 
had for involving decision partners in treatment decisions, rather than measuring their decision 
control preferences with providers. On this scale, for Part A, patients could pick one statement 
out of five that best describes their preferred involvement in treatment decision making. The 
decision control preferences could range from patients reporting: (1) I prefer to make the final 
decision about which treatment I will receive; (2) I prefer to make the final decision about my 
treatment after seriously considering the opinion of my family/friends; (3) I prefer that my 
family/friends and I share responsibility for deciding which treatment is best for me; (4) I prefer 
that my family/friends make the final decision about which treatment I will receive, but seriously 
consider my opinion; or (5) I prefer to leave all decisions regarding my treatment to my 
family/friends. There is also a subcomponent of the Control Preferences Scale, Part B, that 
evaluates patients’ preferences regarding whether their (1) doctor’s input weighs most heavily in 
decision-making; (2) My family/friends' input weighs most heavily; or (3) My doctor's input and 





statistical analysis per category, we grouped answer options in Part A into two categories that 
included high decision control preference and deferred decision style. Response 1 was coded to 
represent high decision control preference (high DCP). Responses 2, 3, 4, and 5 were grouped to 
reflect a deferred decision style. Table 1 describes the two recoded categories.  
Cancer clinical trial participation.  
The primary outcome measure for the study was clinical trial participation among the 
adult cancer patient-participants. Clinical trial participation was determined through medical 
record review and self-report. There were three different responses for this variable, including 
(1) yes, (2) no, (3) not offered/delayed offer.  
Setting. 
Study participants were recruited from the Johns Hopkins Sidney Kimmel 
Comprehensive Cancer Center (SKCCC) outpatient clinic.  The SKCCC was one of the first 
cancer centers in the country designated by the National Cancer Institute (NCI) as a 
Comprehensive Cancer Center. The SKCCC provides care for pediatric and adult patients and 
encompasses a wide spectrum of specialty programs in breast, lung, prostate, pancreatic, colon 
and rectal, melanoma, ovarian, multiple myeloma, hematologic malignancies, and head and neck 
cancers. It is one of two NCI-designated Comprehensive Cancer Centers in the state of 
Maryland.   
Recruitment and Sampling. 
The targeted sample for the quantitative arm of the dissertation study included adult 
cancer patients who had an available therapeutic clinical trial, identified through a medical 
record review and a specific content expert-derived screening algorithm created by research 





therapeutic clinical trial through available algorithms were contacted by phone prior to their 
scheduled oncology visit. The goal of this pre-visit call was to introduce and determine patient 
interest in participating in the parent study. Participants for the dissertation study were first 
screening using the eligibility criteria of the parent study. Inclusion criteria included:  over the 
age of 18, had a primary solid tumor cancer diagnosis (breast, ovarian, colon, lung, pancreas, 
prostate, multiple myeloma, or head and neck), had an identified available therapeutic clinical 
trial, and a Maryland resident. All participants were either newly diagnosed or new referral 
patients in the Johns Hopkins Health System. Exclusion criteria included those persons who were 
not Maryland residents, did not speak or understand English, and who did not have an identified 
available clinical trial identified through EPIC screening.  
Data Collection. 
Quantitative data collection occurred over a 24-month period from March 2016 to March 
2018 in the SKCCC outpatient clinic.  On the day of the oncology visit, informed consent was 
obtained for the parent study and baseline data were collected. In line with the parent study 
protocol, participants received no financial compensation in completing the quantitative arm of 
this study.   
Ethical Procedures.  
Ethical approval for this study was obtained from the Johns Hopkins Medicine 
Institutional Review Board (JHM IRB) (NA_00072282). The study design and questionnaires 
were all approved by the JHM IRB. Participants were told that (a) their participation was entirely 
voluntary, (b) their confidentiality would be protected by de-identifying data and assigning study 
ID numbers, (c) their participation would not affect their care at SKCCC, and (d) they could 





Management System (CRMS) is a web-based tool designed to organize and streamline clinical 
research management and was used in the study for data and safety monitoring.  CRMS is 
maintained in a secure location and accessible to all study team members with a valid Johns 
Hopkins ID. Using a computer-based data entry system, the identifications was entered into 
REDCap, a password protected, HIPAA-compliant, using a Johns Hopkins-based secure study 
server. All hard copies of study data were locked and stored in secure data files at the School of 
Nursing and at a Johns Hopkins Medicine-affiliated building, accessible only to this researcher 
and members of the study team. All screening and completed survey forms that contained 
participant information were scanned into JH Box, a secure university server designed for 
document sharing with other study team members. 
Data Analysis Plan. 
Descriptive and Exploratory Statistics.  First, exploratory data analysis was conducted to 
check for assumptions, outliers, missing data, and data consistency. Graphical methods, 
including histograms, were generated to examine the data. Descriptive statistics were compared 
and used to summarize the sample and instrument characteristics. Baseline demographic data and 
measurement scores were used for the analysis of the aims and hypotheses. Continuous variables 
were summarized using mean and standard deviation (SD) and medians with interquartile ranges 
(IQR).  Categorical variables were summarized using frequencies and percentages.  Sample 
demographics of the sample were calculated, including mean age and standard deviation, 
percentages by gender, frequencies by educational level, marital status, clinical trial offer, cancer 
type, decision control preference, race/ethnicity, and mean clinical trial knowledge, attitudes, and 





A series of scatter plots were conducted and analyzed to determine the appropriate 
covariates to include in the regression models.  Bivariate analyses using Chi-square tests (e.g. 
correlation between two continuous variables, use of a scatterplot, or cross-tabulation with two 
categorical variables) and Fisher’s exact test to examine the associations between variables and 
the p values were also obtained. A p-value of < 0.05 was considered statistically significant. T-
tests were used to examine differences in clinical trial knowledge, attitudes, and beliefs scores by 
gender.  We also performed a one-way ANOVA to determine whether there were any 
statistically significant differences between the mean ages of the three groups of clinical trial 
participation (yes, no, not offered/delayed offer). Due to the smaller percentage of patients who 
were actually offered a clinical trial, we were not able to perform logistic regression to examine 
predictors of the clinical trial participation.  We were able to conduct exploratory analyses, 
including linear regression, to examine predictors of clinical trial knowledge, attitudes, and 
beliefs. Statistical analyses were performed with SPSS statistical software.   
Qualitative Study Methods 
Study Design. An exploratory descriptive design was used to elicit first-hand descriptions of 
individual experiences and perspectives with decision-making related to clinical trial 
participation from the perspectives of adult cancer patients and their decision partners. 
Study Aim:  
AIM 2: To explore the process of decision making about clinical trial participation among 
persons with high levels of decisional control preferences and those with a more deferred 





The goal of the qualitative study phase was to explore how adult cancer patients in the outpatient 
cancer setting, as well as their decision partners, approach clinical trial decision-making based on 
patients’ decision control preferences.   
Recruitment and Sampling.  
Study participants were recruited from the outpatient oncology clinics at the Johns 
Hopkins Sidney Kimmel Comprehensive Cancer (SKCCC), which provides inpatient and 
outpatient care for pediatric and adult patients. Participants in this study phase included both 
patients and decision partners who the patients self-reported, although two patients chose not to 
identify a decision partner for the study. We selected patients who decided to participate and 
those who decided not to participate in a cancer clinical trial, as well as those who were not 
offered a clinical trial at the initial clinic visit when baseline data were being collected for the 
parent study in spite of all patients being screened to have an available clinical trial. Patients 
recruited for the qualitative study were already consented and enrolled into the parent study and 
completed the quantitative phase data collection. Additional inclusion criteria included that the 
patients had completed the Control Preference Scale.  The inclusion criteria for decision partners 
included being 18 years or older, and who were able to read, write and understand English, and 
identified as a decision partner by the patient. Each participant in the qualitative study phase 
received up to $30 and a parking voucher as needed. Sample characteristics are summarized in 
Table 3 in Chapter V. 
Methodology.   
We interviewed patient/decision partner groups from a variety of reported scores on the 
modified version of the Control Preference Scale. Participants were selected for interviews based 





preferences for decision partner involvement into two categories that included high decision 
control preference and deferred decision style. Response 1 was coded to represent high decision 
control preference (high DCP). Responses 2, 3, 4, and 5 were grouped to reflect a deferred 
decision style. Table 1 describes the two recoded categories.  
Table 1. Grouped Categories for Patients’ Decision Control Preferences  
 




“I prefer to make the 
final decision about 
which treatment I will 
receive”  
 
“I prefer to make the final decision about my treatment after 
seriously considering the opinion of my family/friends”  
 
“I prefer that my family/friends and I share responsibility for 
deciding which treatment is best for me”  
 
“I prefer that my family/friends make the final decision about 
which treatment I will receive, but seriously consider my 
opinion”  
 




Data Collection. A semi-structured interview guide was developed by the study team 
through formative exploration of the available literature, clinical experiences and input, and 
informal discussions/review. The factors that influence clinical trial decisions, perceived role of 
decision partners in clinical trial decision-making, and perceptions about clinical trials were 
identified as gaps in the current literature that could be addressed in the qualitative study phase. 
Data collection occurred from November 2017 to March 2018. Interview dates, times, and 
locations were negotiated at the convenience of participants. Interviews were, on average 
approximately twenty-five minutes in length. Interviews took place either via telephone, video, 
or face-to-face. Participants had the option to choose to participate in individual interviews, 





identified a decision partner in order to maximize participants’ comfort level. Each audio-
recorded interview was professionally transcribed verbatim; transcripts were cross-checked for 
accuracy and de-identified prior to analysis.  
Ethical Procedures.  
Ethical approval for this study was obtained from the Johns Hopkins Medicine 
Institutional Review Board (JHM IRB) (NA_00072282). The study design, oral questionnaire 
related to sociodemographic factors of decision partners, oral consent, and the interview guide 
questions were all approved by the JHM IRB. Prior to the start of each interview, oral consent 
was obtained for this additional study phase per the institution’s IRB requirements. Participants 
were told that (a) their participation was entirely voluntary, (b) they could decline to answer any 
question that made them uncomfortable and could add any comments that were not elicited by 
the interview guide, (c) their confidentiality would be protected by de-identifying transcripts and 
demographic questionnaires and using pseudonyms in all reporting of results, and (d) they could 
contact the researchers or the IRB with any questions or concerns. No interview questions were 
unanswered because of participant refusal. Some questions, however, were irrelevant for some 
participants and no response was given. To provide privacy and confidentiality, all participants’ 
names have been omitted, de-identified, and replaced with a numerical pseudonym and only 
those details we interpreted as necessary to understand the findings were reported.   
Data Analysis. 
The final sample size was determined by the number of interviews required to reach 
informational redundancy, and data saturation was determined after conferring with data coders 
and consulting qualitative research mentors. Transcriptions were checked for accuracy, and then 





analyzed the data using the method of hermeneutic phenomenological analysis, which involves 
the reflection on the data, explication of themes, and discernment of patterns to fully understand 
the essence of the lived experience for participants, with a focus on their shared experience 
(Bynum & Varpio, 2018).  Two coders completed line-by-line review of each interview and 
performed the first phase of analysis independently. Transcripts were first read several times 
independently by the two coders to allow for general impressions for the content to develop into 
categories and preliminary codes. Pre-coding, also known as first-level coding, was the first step 
of the analytical process that included circling, highlighting, underlining, or bolding, rich or 
significant quotes or passages that were particularly notable (Saldana, 2016). The data were then 
individually coded and analyzed by both coders who participated in weekly analysis meetings. 
We analyzed a subsample of the coded segments at the beginning of the coding process to verify 
the coding scheme and inter-rater agreement.   
Next, the process of inductive analysis continued as categories emerged from coded 
segments, a process known as second-level coding (Saldana, 2016). We then compared second-
level codes of data to conceptualize the codes into themes that describe the meaning of 
experiences related to the process of decision-making about clinical trial participation. Once a 
codebook was developed, all codes were reviewed and collapsed into categories and themes 
through an iterative process of classifying, comparing, grouping, refining and data reduction 
(Sandelowski, 2000; Bakitas, Dionne-Odom, Jackson, Frost, Bishop, & Li, 2016).  Themes were 
defined as clusters of linked categories that convey similar meaning. The primary coder returned 
often to the audio recordings and transcripts through a recursive process to verify interpretations 
and applications of the codes and themes. Once preliminary findings were decided on between 





coding discrepancies were also brought to the larger study team, and a final decision was made 
after further discussion that included a re-evaluation and comparison of the coded data. After 
receiving input from the research team, study findings were refined, as presented below.  
We enhanced study trustworthiness, including credibility, dependability, and 
transferability (Graneheim & Lundman, 2004) via four strategies. First, we maintained an audit 
trail of study activities, including field notes from each interview. Methodological and analytical 
memos were also used for documenting decisions related to refining and defining codes, 
patterns, or categories as a way to document communications from the research team. This 
allowed the coders to recognize and separate his or her own thought processes from those of the 
participants. Second, the primary interviewer had expertise in both clinical practice and research 
of pediatric and adult cancer patients, and peer and expert reviewers had experienced with 
qualitative analyses focusing on chronic illnesses and family research. Third, at each stage, 
coding was completed by two researchers, and discrepancies were discussed and clarified. 
Fourth, dependability was obtained by having the same researcher conduct all interviews over a 
relatively short period of time (4 months). Overall, data analysis was an iterative process to 
support thematic analysis (Braun & Clark, 2006) that involved discussions of the analytic 











CHAPTER III: Manuscript One:  A Concept Analysis of Decision Partner 
This concept analysis is the first of the three papers that comprises this dissertation. It is the 
author’s intent to submit this paper to Nursing Outlook. The required format for submission is 
American Psychological Association (APA), Sixth Edition with references arranged first 
alphabetically and then further sorted chronologically if necessary. More than one reference from 
the same author(s) in the same year is identified by the letters ‘a’, ‘b’, ‘c’, etc., placed after the 
year of publication.  For this journal, there is no definitive word count for a concept analysis 
article nor a limited number of required references, and abstracts are limited to 150 words. The 
article structure includes clearly defined sections including an introduction, methods, findings, 
discussion and recommendations, conclusions, and appendices.  
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Background: The decision partner concept has primarily been used in oncology. There is a need 
for greater precision and consensus surrounding its conceptual definition and use in broader 
populations. 
Purpose: The purpose of this concept analysis was to define and describe the decision partner 
concept within the context of healthcare decision making.   
Methods: The Walker and Avant method of concept analysis was applied to explain the 
antecedents, attributes, related concepts, and consequences of the concept, with major themes 
identified.  
Discussion: A unifying definition and discussion of the decision partner concept is proposed. 
Our analysis offers promising direction in refining the concept across various diseases and 
medical encounters.   
Conclusion: Findings have implications for reforming policy, practice, and research by drawing 
attention to developing conceptual frameworks and empirical research that refine its antecedents, 
attributes, consequences, and instruments to measure the concept to lead to interventions that 
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In medical encounters, patients make complex healthcare decisions and often involve and 
rely on family members in decision-making. Undoubtedly, decision-making occurs within the 
context of wider social networks and is not necessarily only a dyadic process between the patient 
and the health-care provider, which previous published literature in this area has tended to 
assume (Schumm, Skea, McKee, & N’Dow, 2010; Ballard-Reisch & Letner, 2003). Given the 
numerous decisions that patients make in short periods of time, families’ impact on patients’ 
decision making can be profound (Zhang & Siminoff, 2003). For the context of this article, 
family is defined as any individual who plays a significant role in another person’s life and can 
be an intimate partner, spouse, close friend, or blood relative. Family members are relied upon 
for both emotional and practical support (Shin, Cho, Roter, Kim, Sohn, Yoon, Kim, Cho, Park, 
2013), and the nature and degree of family involvement can be highly variable (Hobbs et al., 
2015; Laidsaar-Powell et al., 2016a; Shin et al., 2013).   
Although, patient autonomy, or the capacity to make decisions independently, is greatly 
recognized and valued in health care, there is a need to acknowledge that patients do not always 
make decisions in isolation.  From an ethical standpoint, Beauchamp and Childress have 
maintained the principle of “respect for autonomous choices of persons”, however, they then 
quickly add that they see autonomy as being neither a rejection of the “social nature of 
individuals” (DuBois, 2007; Qualtere-Burcher, 2009).  The principle of autonomy posits that 
human beings are capable of making rational choices that determine their actions and themselves 
(DuBois, 2007). However, in order to be autonomous, a person must not only understand the 
information about a decision, but they must be able to use it (Herring, 2016). In this article, we 





beings insofar as they are essentially related to other human beings (DuBois, 2007). This 
principle recognizes that in order to flourish, actions must respect the relationships that an 
individual is in or should be in (DuBois, 2007). Ethicists argue that people develop their 
understanding of self and their goals in terms of relationships with others (Herring, 2016).  
Therefore, understanding the structure and enactment of the decision-maker role in 
family interaction can provide insight into how individuals and/or family members perform the 
decision-making role within a cultural context that values autonomy and self-determination in 
combination with collective family actions in decision-making (Trees, Ohs, & Murray, 2017). 
Inarguably, family members can have an influential role in shared decision-making, with a goal 
of arriving at decisions that meet the patient’s needs at that point in time (Clayman, Gulbrandsen, 
& Morris, 2017). Therefore, it is important to expand the concept of shared decision-making to 
not only capitalize on the patient-clinician relationship, but also to foster an interactive process 
whereby patient, family, and clinician can negotiate an agreed-upon decision (Montori, Gafni, & 
Charles, 2006; Bae, 2017; Alden et al., 2017).  Specifically, more attention should be given to 
explicitly define and describe these decision partners, who are the family, close friends, and 
others engaged in healthcare decision-making with the patient by conducting a concept analysis.   
Selection and Purpose of the Concept Analysis 
The first step in a concept analysis is the selection of a concept. Concepts are important 
building blocks of knowledge, thought and communication, but to be truly useful they must be 
defined and clarified (Wahlin, 2017; Waltz, Strickland, & Lenz, 2010).  For this concept 
analysis, decision partner was the concept that was chosen as the area of focus. Understanding 
this concept is critically important, particularly as patients with varying health conditions and 





Undiscerning to any singular health condition, the decision partner concept recognizes that many 
patients rely on and are influenced by close family and friends in healthcare decision-making. 
These individuals (family, friends) have been referred to and studied in many ways, but more 
efforts must be made to address their role and unique contribution in healthcare decision-making. 
Currently, there is a noticeable absence and lack of a clear definition of the decision partner 
concept as well as a diffuse understanding in the literature. 
The second step in the concept analysis is to determine its purpose, which is to provide an 
initial introduction to reveal the state of the science around the decision partner concept. In 
general, the concept analysis offers a vehicle for identifying the shared meaning of related 
concepts, explaining why those meanings have developed, and describing how a distinct concept 
can be applied in real-life contexts. It is a strategy to examine the attributes or characteristics of a 
concept (Walker & Avant, 1994). Through a rigorous process, this concept analysis contributes 
to a body of knowledge that can help to identify, explore, clarify, validate, and define a concept, 
as well as clarify overused terms with ambiguous meaning. We aim to identify antecedents, 
attributes, consequences, and a present definition of the decision partner concept that will add to 
the understanding of its use in healthcare decision-making.   
Methods 
Literature Review  
A search of relevant health and medical databases, including PsychINFO, PubMed, 
Embase, and CINAHL, was conducted with the assistance of a reference librarian to identify and 
clarify the uses, content, and conceptualization of the decision partner concept. The literature 
search was used to construct conceptual and operational definitions of its defining characteristics 





decision making, partner, decision support networks, relational autonomy, decision maker, 
making decisions, adult, family, dyad, interpersonal, decision control, social support, and 
decision partner, and used in various combinations while conducting the search. Articles from 
the literature search focused on persons outside of healthcare professionals with whom patients 
make decisions about care. Inclusion criteria included: English language, human subjects, case 
studies, systematic reviews, original research and secondary analyses in peer-reviewed journals, 
and decision making whether in the context of health care or treatment decision-making.  
Research designs included peer-reviewed research studies using mixed-methods, quantitative or 
qualitative studies as well as review papers focusing on health care decision making. We 
excluded sources that were not peer reviewed and not published in English, as well as those with 
unavailable full-texts. The titles and abstracts of the resulting literature were screened to 
eliminate articles that did not meet the inclusion criteria. Full-text articles were screened to 
further assess contextual information congruent with the decision partner concept, and articles 
and reference lists were then reviewed for relevance.  The literature search in the presented 
databases and data selection process resulted in 112 papers included in the concept analysis 
(Figure 1). Key themes related to decision partner concept were identified and categorized into 







Search terms: decision* NEAR/3 partner*, decision making, partner, decision 
support networks, relational autonomy, decision maker, making decisions, adult, 
family, dyad, interpersonal, decision control, social support, and decision partner 
 
Databases: PsychINFO, PubMed, Embase, and CINAHL 
 
Inclusion Criteria: publications using the term decision partner or some combination 












Figure 1 – Literature Review Methods and Results 
 
Methodology 
We applied the theoretical approach from Walker and Avant Method (1995) for the 
concept analysis of decision partner. We chose this method due to its widespread use and its 
systematic approach. Many authors have successfully used this process in clarifying concepts. 
Some examples of include Bennett and colleagues (2017) examining the concept of care partner, 
Kowalik & Yoder (2010) examining decisional involvement, social support examined by several 
authors (Finfgeld-Connett, 2007; Langford, Bowsher, Maloney, & Lillis, 1997), Hutchfield 
(1999) examining family-centered care, patient participation examined in the context of a nurse-
patient relationship (Sahlsten, Larsson, Sjostrom, & Plos 2008; Cahill, 1996), Chou (2000) 
examining caregiver burden, and the empowerment concept examined by Ellis-Stoll & Popkess-
Vawter, (1998). This form of concept analysis is not a linear activity but rather a circular 
process, moving back and forth between steps (Kvæl, Debesay, Langaas, Bye, & Bergland, 
2018).  We identified and presented the eight steps of this method to guide the examination of 




Excluded: duplicates, conference abstract only, health professionals as decision 
partner, pediatrics, non-English full text, unpublished thesis, full-text unavailable, 
not health related 
 
Step 3 





Walker and Avant (2005): The Eight Steps of a Concept Analysis 
1. Select a concept. 
2. Determine the aims.  
3. Identify all uses of the concept.  
4. Determine the defining attributes.  
5. Construct a model case.  
6. Construct borderline, related, contrary, and model cases.  
7. Identify antecedents and consequences.  
8. Define empirical referents.  
Figure 2 – Steps of the Walker and Avant Method for a Concept Analysis.  
Findings 
Definition 
While there are many definitions of the word decision, we have chosen to adopt the 
definition of decision as “the act of deciding; a conclusion or resolution reached” (Noone, 2002).  
Additionally, decision-making is defined as the “cognitive process of reaching a decision” 
(Tariman, Berry, Cochrane, Doorenbos, & Schepp, 2012), and can be stressful as it often 
involves consideration weighing available treatment, benefits and risks, uncertainty, and the 
potential for associated burden for patients and important others (Siminoff, 2013; Palmer-
Wackerly, Krieger, & Rhodes, 2017). Partner is defined according to Merriam-Webster as “one 
associated with another especially in an action”, “one that shares”, “a member of a partnership” 
(Merriam-Webster Dictionary, 2017).  The concept of partnership was first used in the context of 
business and economics, whereby partners assumed an equal share of the profits and losses, as 





been extended to the field of health and social care, with the historical emphasis shifting from 
care providers acting in the role of experts to taking on the role of partners of their clients 
(Gallant et al., 2002).  There is also a growing need to recognize and include third-party 
members, such as family or close friends, in this healthcare partnership. Partnership refers to “a 
shared commitment, where all partners have a right and an obligation to participate and all will 
benefit from the partnership” (Ying & Loke, 2016). The combination of these two definitions of 
decision and partner form to create the decision partner concept, which describing someone who 
shares in the act of making a decision with another person.   
Use of Concept in the Existing Literature 
The third step in the concept analysis is the identification of the many uses of the concept 
in literature sources. To date, the decision partner concept has not been commonly used in the 
literature, see Figure 3. Wenzel et al. (2015) first introduced the term following an analysis of 
qualitative interviews that revealed the potential influence of family and friends in making 
patient decision-making about clinical trial participation in their Model of Cancer Clinical Trial 
Decision Making (Wenzel et al., 2015).  Distinct from Wenzel’s initial usage, Clayman et al. 
(2017) expanded the definition beyond clinical trial decision-making to encompass all healthcare 
related decisions. Clayman and colleagues noted that not all caregivers or family members are 
engaged in health care decision making and that terms, such as caregivers, should not be 
conflated with decision partners, whom are engaged in health care decision making (Clayman, 
Gulbrandsen, & Morris, 2017).  Clayman and colleagues recognized that decision partners are 
essential contributors to patient decisions (Clayman, Gulbrandsen, & Morris, 2017).  Lastly, the 
decision partner concept has most frequently been referred to a significant other (spouse), child, 






Figure 3 – Number of decision partner publications from 1990-2017.  
 
Defining Attributes  
The fourth step in the concept analysis of decision partner is to determine the defining 
attributes. Defining attributes are characteristics of the concept that appear repeatedly in the 
literature, and they are most frequently associated with the concept allowing the broadest insight 
into it (Walker & Avant, 2011).  Defining attributes are associated with the concept and 
differentiate the concept from related concepts (Bennett, Wang, Moore, & Nagle, 2017). The six 
defining attributes of the decision partner concept are found in Table 1 and include: (1) having a 
trusting relationship with the patient, (2) demonstrates a willingness to participate in decision-
making, (3) articulates a clear understanding of both the patient’s health condition and the 
decision that must be made, (4) demonstrates decision-making self-efficacy, (5) exemplifies an 
emotional capacity to participate in decision-making, (6) willingness to fulfill several supportive 
roles as needed. 





The first attribute of a decision partner is that he or she must have a trusting relationship 
established with the patient. With having a trusting relationship with the patient, there is an 
assumption that the decision partner has perceived knowledge of the patient and can be either a 
family member, close friend, spouse or cohabitating partner or significant other to the patient. 
(2) Demonstrates a willingness to participate in decision-making. 
 The second attribute of a decision partner is that he or she has a willingness to be a part 
of the health care decision-making process with the patient. The decision partner must have a 
desire to participate, question, challenge and seek information. He or she does not necessarily be 
physically present or in close proximity with the patient but must be available and accessible.   
(3) Articulates a clear understanding of both the patient’s health condition and the decision that 
must be made.  
 The third attribute of a decision partner is that he or she must be able to articulate a clear 
understanding of both the patient’s health condition and knowledge about the decision that must 
be made in order to adequately contribute as a decision partner. He or she should bring personal 
knowledge on the suitability of different treatments for the patient’s circumstances and 
preferences (McGinnis et al., 2013), and provide the doctor with information about the patient’s 
medical history or symptoms (Wolff, Clayman, Rabins, Cook, & Roter, 2012). This 
understanding allows the decision partner to engage in decision-making fully and responsibly in 
a way that optimally benefits the patient.   
(4) Demonstrates decision making self-efficacy 
The fourth attribute of a decision partner to exhibit self-efficacy in decision-making. It is 
well-understood that it can be difficult to sort through an overwhelming amount of information 





Therefore, decision partners should also be able to demonstrate decision making self-efficacy in 
their role. Self-efficacy refers to individuals’ beliefs regarding their capability to produce 
designated levels of performance that exercise influence over events (Lopez & Guarino, 2013). 
According to the Surrogate Decision Making Self-Efficacy Scale (SDM-SES), components of 
self-efficacy for decision making include (1) knowing when to make decisions, (2) ability to 
obtain information to make informed decisions, (3) ability to weigh risks and benefits of 
treatment options, (4) ability to make the best treatment decisions, and (5) knowing what 
treatment options the individual patient would select (Lopez & Guarino, 2013). Decision-making 
self-efficacy includes an assertiveness and confidence to openness discuss the health care 
decision options with the patient and medical team.  
(5) Exemplifies an emotional capacity to participate in decision-making 
 The fifth attribute of decision partners include having an emotional capacity to participate 
in decision-making (Zeliadt et al., 2011). One study found that a major factor in what family 
members want to hear or can absorb is, of course, their emotional state (Billings, 2011). Shock 
and denial are common reactions to distressing information, even when family members think 
they are prepared (Hebert, Dang, & Schulz, 2006) or when the [bad] news seems to clinicians 
like an obvious culmination to a serious chronic illness (Billings, 2011).  There can be emotional 
discomfort, including intrapersonal tensions and inner emotional conflicts (Jezewski, 1994), 
especially when one must make ‘life or death’ decisions (Schenker, Crowley-Matoka, Dohan, 
Tiver, Arnold, & White, 2012). Therefore, decision partners exhibit traits of being emotionally-
ready to participate in decision-making. 





The sixth attribute of a decision partner is being able to fulfill a variety of supportive 
roles as needed for the patient during the decision-making process. Roles may include serving as 
the patient advocate by defending the patients’ interests, giving useful information and asking 
questions to know more about the treatments (e.g. alternatives, potential benefits/consequences) 
(Lamore, Montalescot, & Untas, 2017). The decision partner may also serve as the ‘hub of 
information’ for the patient, which means to gather information about a decision that must be 
made as well as obtain shared information and knowledge about the patient (Reeves et al., 2015). 
This role also entails obtaining the patient’s opinion, expectations, and experiences and 
providing individually adapted information/knowledge (Eldh et al., 2004; Henderson, 2002; 
Sainio, Lauri, & Eriksson, 2001; Sainio & Lauri, 2003; Tutton, 2005; Sahlsten et al., 2008), 
acting as a ‘messenger’ or ‘middleman’ (Laidsaar-Powellc, Butow, Bu, Fisher, & Juraskova, 
2016), and translating and passing on information to other family members (Quinn et al., 2012) 
who are present or outside of the medical encounter. Their role may also include summarizing 
the information given by the clinician, and repeat or filter information (Lamore, Montalescot, & 
Untas, 2017; Laidsaar-Powell et al., 2016b; Laidsaar-Powell et al., 2016c), and acting as a 
surrogate decision maker or translator (Reeves et al., 2015).  
Model, Borderline, and Contrary Cases 
 
 To contribute to the decision partner concept analysis, model, borderline, and contrary 
examples can be used (Walker & Avant, 2011). We presented these examples below to provide a 
better understanding of decision partner, given the multiple defining attributes of the concept.  
Model Case 
A model case example is one that includes all defining characteristics of the concept.  In 





had an upcoming appointment with his new oncologist. Lee decided to invite one of his adult 
daughters to accompany him on the visit and help remind him to ask certain questions. Lee’s 
daughter, Sarah, does not live close by and made a special trip to accompany him on the visit. 
However, her father regularly calls her on the phone to include her in the medical visits and 
discussions about decision-making. In her role as a decision partner, Sarah provides the clinician 
with detailed information related to her father’s medical history and weighs in about different 
treatment options that are presented to him. Sarah knows her father well. She helps him to 
process information, discusses the risks and benefits involved, as well as provides support and 
encouragement. She often asks questions to the medical team and communicates with her sister 
following each visit in order to update her on the health care decisions as well. This is an 
example of a model case of the decision partner concept.  
Borderline Case 
A borderline case is where the use of the concept has some but not all concept 
characteristics (Walker & Avant, 2011). In the case of Jim, he is an elderly patient with type 2 
diabetes who was admitted to the hospital following an acute stroke. Jim is slowly recovering 
from the stroke and has recently appointed his adult son Jarrett as his medical power of attorney. 
Although Jarrett lives across the country and talks to his father a few times a year, he still 
considers himself to have a fairly good relationship with Jim, although at times their relationship 
is estranged. Jarrett often does not feel knowledgeable enough to make decisions with the 
medical team, he is emotionally withdrawn, and having difficulty coping with his father’s health 
condition. This case is a clear example of what it means to lack vital attributes of a decision 





capacity, demonstrate decision-making self-efficacy, and articulate a clear understanding of her 
father’s health condition and the decision that must be made. 
Contrary Case 
A contrary case is one where the concept of decision partner is used contrary to the 
identified attributes of a decision partner.  In the case of Stacy, she is a 39-year old female 
patient with uncontrolled hypertension and kidney failure. Stacy was recently admitted to the 
acute inpatient unit following a risky surgery. After surgery, she faced several complications, 
including an uncontrolled blood pressure, increased fluid retention, and a rise in her electrolyte 
levels. Her disabling condition is critical, yet Stacy does not have legal documents such as a 
living will to cover decisions about her health matters. She has been assigned a court-appointed 
legal guardian for her health-related matters. The role of her court-appointed legal guardian, 
Larry, is to make decisions, give consent to health-related decisions, and facilitate 
communication between health care provider and patient, though not acting as a decision partner 
for Stacy. Larry knows very little about her medical history, social history, and current health 
condition, and he is neither family nor friend. Larry does not necessarily advocate for treatment-
related goals that are based on Stacy’s personal preferences and values, nor does he 
communicate regularly with Stacy or her family to better understand her goals of care.  A health-
related decision must be made about her plan of care, but it is important to discern whether Larry 
has adequate information to arrive at a decision and whether he is making these decisions in her 
best interests. This is an example of a contrary case of the decision partner concept.   
Related Concepts 
A related concept is identified as a concept that is related to the decision partner concept 





1) Decision-support person, decision-support networks, partner decisional support 
Decision-support persons, decision-support networks, or partner decisional support are inter-
related and are often seen in the literature as family and friends who contribute to treatment 
decisions made by patients and are considered to be both important and influential (Wallner et 
al., 2017). Decisional support is defined as social support given and received during a decision-
making context (Krieger, 2014; O’Connor, 2006; Milata, Otte, & Carpenter, 2018).  In a study 
by Palmer-Wackerly and colleagues (2017), it was found that partner decisional support may 
partially mediate the relationship between health care provider (HCP) support and patient 
decision-making satisfaction. Decisional support is different from other definitions of social 
support that focus on the quantity, frequency, structure, and availability of perceived social 
support (Goldsmith, 2004; Palmer-Wackerly, Krieger, & Rhodes, 2017).  These related concepts 
differ from decision partner in that decision partners are involved more broadly in health care 
decisions, not just specifically treatment decision-making. 
2) Carer 
Similar to decision partners, carers can also facilitate the process of deliberation by 
obtaining information about treatments, discussing information with the patient, eliciting 
information from clinicians, and act as sounding boards for the patient to help stimulate thinking 
about treatment decisions and processes behind the scenes (Hubbard et al., 2010). However, their 
primary roles are not related to decision-making. In the literature, carers have been largely 
defined as those persons who provide assistance, and are frequently spouses, siblings, children, 
other relatives, or friends (Bennett, Wang, Moore, & Nagle, 2017). They are seen as providing 
the majority, if not all, of the care for a person who is unable to independently manage their own 





been described as “hope carriers”—as those who remain hopeful even when those they are caring 
for feel hopeless (Bradley & Green, 2018; Marshall, Deane, Crowe, White, & Kavanagh, 2013).  
3) Caregiver 
Caregiver is commonly defined as a person who has a close relationship with the patient 
and provides assistance with the coordination of care, symptom management, disability, 
mobility, medications, and dressing (Lim & Zebrack, 2004; Bennett, Wang, Moore, & Nagle, 
2017).  In her analysis of the concept of empowerment of family caregivers, Sakanashi et al. 
(2017) described how engagement in health care decision making was one dimension of 
empowerment of caregivers.   
4) Care partner 
The defining characteristic of the care partner concept is the existence of a person with a 
health condition requiring some assistance with health care needs (Bennett, Wang, Moore, & 
Nagle, 2017). The term care partner recognizes the interdependent and often reciprocal 
relationship between two or more persons who enact caring roles towards one another (Womack, 
Isaksson, & Lilja, 2016). Care contexts range from acute medical needs to long-term and end-of-
life care (Bennett et al., 2017). Care partners are predominantly family members, frequently the 
spouse, cohabitating partner, or those persons who are in a romantic relationship with the patient 
(Bennett et al., 2017; Rini et al., 2011; Manne et al., 2012), and refer to individuals who function 
in unpaid or informal roles (Womack, Isaksson, & Lilja, 2016). They can provide ADL support 
to high level care, assist with health care information facilitation, medical appointment 
coordination, hospital care assistance, monitoring vital signs, home care assistance, coordination 
of community and government assistance, coordination of family member involvement, 





partners has been a component of the analysis of broader concepts such as care partners (Bennett, 
2017) and parent participation (Vasli, 2014). 
5) Study partner 
Previous investigators had used the term study partner to refer to family members, 
friends and others who participated in patients’ decision to enroll in a clinical trial and noted that 
some study partners became participants in the study themselves, thereby adding some confusion 
to the role (Black, Taylor, Rabins, & Karlawish, 2014; Karlawish, Kim, Knopman, Dyck, James, 
& Marson, 2008).  Researchers have described the role of study partner as an informant for the 
patient-subject, and a decision-maker either as a surrogate for subjects who lack decisional 
capacity or a participant in joint decision-making with those who are less cognitively impaired 
(Black, Taylor, Rabins, & Karlawish, 2014; Grill, Monsell, & Karlawish, 2012). Their 
responsibilities include managing the logistics of study participation and provide comfort and 
encouragement for the patient-subject (Black, Taylor, Rabins, & Karlawish, 2014). They differ 
from decision partners in that they specifically focus on clinical trial-related decisions and have 
been described to be involved in decision-making with patients with cognitive impairments, 
while decision partners are involved in a wider range of health care decisions.  
6) Close other 
Close others can be defined as individuals such as a partner, family, and friends who 
patients seek out for advice and comfort (Rini et al., 2011). More simply, Acar-Burkay and 
colleagues define close others as close friends (2017). In other literature, close others have been 
referred to as romantic partners (Etcheverry & Agnew, 2008), family and friends (Hughes & 





partners in that their role is not explicit to a particular action such as decision-making or 
caregiving. 
7) Surrogate or proxy decision maker 
Surrogates are typically family members who are entrusted with the authority to make 
health care decisions for decisionally incapacitated patients, and patients who are too ill 
(Schenker et al., 2012), unable to express their treatment preferences (Majesko, Hong, Weissfeld, 
& White, 2012), have progressive cognitive impairment (Elliott et al., 2009; High & Rowles, 
1995) and those who are dying (Dionne-Odum et al., 2015). Surrogates differ from decision 
partners in that they often make decisions in the absence of the patient’s input. They are expected 
to make decisions that approximate as closely as possible the choices patients would make were 
they able (Beauchamp & Childress, 2012; Dionne-Odum et al., 2015; Winter & Parks, 2008).  
8) Accompanying person or companion 
In the literature, an accompanying person (AP) is defined as a family member or close 
relative who is present in a clinical consultation when information is shared between doctor and 
patient (Lee, Teo, & Kanesvaran, 2018; Andrades, Kausar, & Ambreen, 2013). An AP has also 
been described elsewhere (Ekwall, Gerdtz, & Manias, 2009), in the context of emergency room 
visits, as the individual who plays a vital role in delivering psychosocial support to the patient. 
The primary role (68.6%) of an AP is to be a patient advocate, as Botelho et al. (1996) describes 
in their work examining behavior and preferences of patients regarding family involvement in 
routine health care visits.  Similar to an AP is the term companion. Companions accompany 
patients to the medical visit and can help patients provide physicians with essential medical 
history as well as reinforce, verify, and augment patients’ statements (Street & Gordon, 2008; 
Clayman et al., 2005).  Companion behaviors were broadly categorized in relation to enhancing 





facilitating patient involvement (Wolff, Clayman, Rabins, Cook, & Roter, 2012). Alternatively, 
autonomy detracting behaviors were also identified and include (1) controlling actions towards 
the patient as well as (2) alliance building with the doctor (Wolff, Clayman, Rabins, Cook, & 
Roter, 2012). In comparison, the companion or AP may or may not be involved in decision-
making, while DPs are involved. Predominantly, their role is to be a supportive physical 
presence for the patient, which is not necessarily true for DPs who are sometimes not able to be 
present with the patient.  
 
Identification of Antecedents and Consequences  
The seventh step in the concept analysis is the identification of antecedents and 
consequences (Walker & Avant, 2011). Antecedents are factors that are required for the concept 
to occur and exist (Bennett, Wang, Moore, & Nagle, 2017). Antecedents for the concept of 
decision partner are both practical and behavioral factors that span across different health 
conditions and diseases.  The consequences of the decision partner concept, for patients, 
families, clinicians, and healthcare organizations, are evident. Introducing and implementing this 
concept can impact the way in which the healthcare system includes the role of others in 
healthcare decision-making and emphasize the unique contribution they often bring to the 
decision-making process. 
Antecedents of the Decision Partner Concept:  
1) There is a health care decision that must be made.   
First, in order for the decision partner concept to exist, there must be a health care 






2) There is an established trusting relationship between the patient and the decision partner.  
Secondly, the concept of decision partner requires an established trusting relationship 
with the person who has to make a health-related decision. Trust is indispensable to all social 
relations (Acar-Burkay, Fennis, & Warlop, 2014) and is defined as an individual’s willingness to 
accept vulnerability based upon positive expectations of the intentions or behavior of another 
(Rousseau, Sitkin, Burt, & Camerer, 1998).  In addition, trust can also be defined as the reliance 
on others (Gonzalez, 2017; Mieize-Growchowski, 1984).  At the interpersonal level, trust 
enhances cooperation (McAllister, 1995) and information sharing (Butler, 1999), which is 
critical in decision-making (Acar-Burkay, Fennis, & Warlop, 2014). 
3) The patient perceives and recognizes the decision partner as an essential contributor in 
decision making.  
Thirdly, in order for the decision partner concept to exist, the patient who is making a 
health-related decision should perceive and recognize the decision partner as important, in many 
cases, essential contributors to patient decisions and their desire and capacity to follow through 
on managing the plans made (Clayman, Gulbrandsen, & Morris, 2017). This antecedent is 
critical to the concept because it focuses on the notion that the patient values and cares about the 
opinion of another.    
4) The patient has a participatory style of decision making.   
Patients who have intact decision-making capacity vary considerably in their decision 
control preferences (Nolan et al., 2007). Some prefer to make decisions independently, while 
others prefer to defer decision-making authority to loved ones or physicians, and most would opt 
for shared decision-making (Nolan et al., 2007). For the decision partner concept, it is important 
to establish an understanding of the patient’s preferred level of decision partner involvement in 





Consequences of the Decision Partner Concept:  
The consequences of introducing the decision partner concept include:  
1) Broad enough to include non-family decision partners 
 The decision partner concept is broad enough to include family and non-family decision 
partners because health care decisions will undoubtedly impact their lives as well. John Hardwig 
stated in the Hastings Center Report (1990) that there is no way to detach the lives of patients 
from the lives of those who are close to them. He described “family” means “those who are close 
to the patient”, and often includes close friends and companions, recognizing that the word 
“family” has many meanings (Greogry, 2004).  
2) Confusion about whether this concept refers to health professionals or lay persons. 
 There is potential confusion about whether this concept refers to or can also include 
health professionals in addition to lay persons. For instance, information giving has been an 
essential part of the nurse’s role in clinical practice, as does promoting patient autonomy and 
advocacy (Tariman & Szubski, 2015). However, it is important to note that decision partners are 
selected by the patient and must have a relationship and be knowledge about the patient in order 
to be engaged in decision-making, which is not necessarily true regarding health professionals.  
3) There is potential for decisional conflict in healthcare decision making. 
When decision partners are present in healthcare decision-making, there is potential for 
discordant views on the decision that must be made. Individuals may place different values on 
different outcomes related to the decision or may enter into a clinical consultation with different 
goals (Lee, Teo, & Kanesvaran, 2018). For example, the patient may want to obtain a clear 
understanding of the disease condition and the decision partner may be seeking the best 





and provide emotional comfort and psychological support (Lin, Huang, & Chen, 2017), there are 
instances when disagreement can arise between the patient, decision partner, and clinician. 
Certain behaviors may also be exhibited including nagging, trying to take control of the decision, 
or acting angry or disapproving. They could also be planning to set and promote their own 
agenda instead of that of the patient (Street & Gordon, 2008; Heid, Zarit, & van Haitsma, 2016). 
In a study investigating the full “triad” of patients, oncologists, and caregivers in cancer 
treatment decision-making, LeBlanc and colleagues (2017) found that patients, caregivers, and 
oncologists have significantly different preferences about both treatment decisions and the 
decision-making process. The researchers found that triad members frequently disagreed about 
the “correct” treatment choice (LeBlanc et al., 2017). These divergent opinions (Rini et al., 
2011), values and priorities could counter patients’ autonomy and best interests (Ho, 2008), and 
their decisions may not accurately reflect patient’s values and result in discordant preferences 
(Vig et al., 2007; Schenker et al., 2012; de Boer et al., 2015; Shin et al., 2015).  
4) There is potential for patients to have more than one decision partner 
Often families have multiple decision makers rather than one primary decision maker as 
preferred by the clinicians (Quinn et al., 2012), and each person may play a different role in the 
decision-making process. Subsequently, the need to consider the wishes of other family members 
may pose a barrier to clear decision-making (Parks, Winter, Santana, Parker, Diamond, Rose, & 
Myers, 2011), thereby making decision-making more difficult (Schenker et al., 2012).  Multiple 
decision partners may result in multiple individuals asking a lot of questions (Coats et al., 2018), 
and requiring the medical team to divide their attention between the patient and family. 





making is important in facilitating more effective interaction and consensus among family 
members and reducing conflict among family and clinicians (Quinn et al., 2012).  
5) Emotional and psychological burden related to decision-making 
The decision partner concept can also result in increased emotional and psychological 
burden for potentially the patient, clinician, and decision partner in different ways. The patient 
may report emotional and psychological burden about involving a third-part, an additional 
person, in the decision-making process as well as express feelings of not wanting to disappoint 
the decision partner in the decision that was made. Secondly, the clinician may recognize 
decision partners as ‘important’, ‘essential’, ‘critical’, or ‘imperative’ (Laidsaar-Powell et al. a, 
2016), but challenges can arise when they become controlling, dominant, manipulative, or 
requesting non-disclosed information. Acknowledging family members’ interests would bring 
benefits as well as burdens to medical practitioners (Hardwig, 1990). Decision partners may 
suffer from emotional and psychological burden as well. Feelings can include feeling burdened, 
(Wendler & Rid, 2011; Braun, Naik, & McCullough, 2009; de Boer et al., 2015), and stretched 
beyond their capacity (Holroyd-Leduc et al., 2016). They may also feel a sense of grief, anxiety, 
stress, guilt as well as doubt regarding whether they had made the right decisions (Wendler & 
Rid, 2011).  In addition, they may find difficulty in making decisions under a time pressure (de 
Boer et al., 2015).  In the context of surrogate decision-making, Swigart, Lidz, Butterworth, & 
Arnold (1996) reported that surrogates repeatedly “searched their own sense of morality” about 
making decisions that could be life-threatening. Therefore, it is important to recognize the 
emotional and psychological burden that all stakeholders may face.  





The presence of decision partners may allow for more opportunity to focus on patient 
goals and values for health care decisions. They may help to prioritize goals of care in line with 
the values and preferences of the patient (de Boer et al., 2015), relay the patients’ questions and 
concerns to the physicians and vice versa (Lamore, Montalescot, & Untas, 2017; Lin, Pang, & 
Chen, 2013) and help during the consultations when the patients are distressed (Lamore, 
Montalescot, & Untas, 2017; Lin, Huang, & Chen, 2017). Their presence could consist of 
helping patients in seeking, organizing, and processing information for health decisions, 
including finding a health care provider, receiving advice about treatment, and describing 
symptoms to providers (Krieger et al., 2015; Siminoff et al., 2006; Palmer-Wackerly, Krieger, & 
Rhodes, 2017).  
7) Increased patient engagement in decision-making   
The presence of decision partners could result in increased patient engagement in 
decision making. Studies have found that family involvement in patient care enhances patient’s 
autonomy rather than detract from it (Shin et al., 2013; Clayman, Roter, Wissow, Bandeen-
Roche, 2005), and has been associated with greater question-seeking, less passive agreement 
with physician information, less social talk, and more orienting statements (Wolff, Clayman, 
Rabins, Cook, & Roter, 2012).  Family involvement has been shown to support patient 
engagement particularly for vulnerable patients such as those who are older, less literate, 
mentally or cognitively impaired, who have sensory or functional deficits, or who must manage 
complex treatment regiments (Wolff, Clayman, Rabins, Cook, & Roter, 2012; Katon, 2008).  
8) Emphasis on relational autonomy  
 The decision partner concept constitutes a shared approach to decision-making that draws 





autonomy occurs when individuals work alongside those they are in close relationships with, 
seeking compromises that are good for ‘us’ rather than weighing up competing interests 
(Skyrme, 2016). When considered as an individualized quality that is disassociated from 
relational contexts, autonomy fails to account for joint decision-making (Carnevale, 2012). 
Hence, the decision partner concept places emphasis on relational autonomy, which recognizes 
the importance of social circumstances and significant relationships on individuals’ self-
determination (Bell &Balneaves, 2015; Beauchamp & Childress, 2012; Sherwin, 1998).  
9) Loss of privacy for patients 
A challenge with the decision partner concept is the issue of maintaining patient privacy 
(Laidsaar-Powellc, Butow, Bu, Fisher, & Juraskova, 2016) and recognizing patient feelings of 
discomfort about involving others in decision-making and sharing personal medical information 
in discussions. When given access to private health-related information, the decision partners 
become co-owners of someone else’s information (Bute, Petronio, & Torke, 2015).  
Alternatively, it is also important to recognize the current emphasis on privacy and 
confidentiality in today’s health care, which may make decision partner roles more challenging.  
10)  The decision partner is not well-informed about the decision that must be made. 
It can also be a possibility that the decision partner is not well-informed about the 
decision that must be made.  When this happens, it can impact the patient’s decisions and 










Table 1 – Decision Partner Concept Components 
 
Antecedents Attributes Consequences 
 
1. There is a healthcare 
decision that must be 
made by the patient.  
1. Has a trusting relationship 
with the patient.   
1. Broad enough to include non-
family decision partners. 
 
2. There is an established 
trusting relationship 
between the patient and 
the decision partner. 
 
2. Demonstrates a willingness 
to participate in decision-
making.  
2. Potential confusion about 
whether this term refers to health 
professionals or lay persons. 
 
3. The patient perceives 
and recognizes the 
decision partner as an 
essential contributor.   
 
3. Articulates a clear 
understanding of both the 
patient’s health condition 
and the decision that must 
be made. 
 
3. Potential for decisional conflict 
in healthcare decision making.  
4. The patient has a 
participatory style of 




4. Potential for patients to have 
more than one decision partner. 
 5. Exemplifies an emotional 
capacity to participate in 
decision-making.  
  
5. Emotional and psychological 
burden related to decision-
making. 
 
 6. Willing to fulfill several 
supportive roles as needed, 
including patient advocate 
and the “hub of 
information”. 
6. Promotion of incorporating 
patient preferences 
  7. Increased patient engagement in 
decision making 
 
8. Emphasis on relational 
autonomy 
 
9. Loss of privacy for patients 
 
10. The decision partner is not well-
informed about the decision that 
must be made. 









Empirical Referents  
The eighth and final step in the concept analysis is the identification of the empirical 
referents. These are classes or categories of actual phenomena which by their existence or 
presence demonstrate the occurrence of the concept itself (Wahlin, 2017) by providing specific 
measurable examples to verify the presence and subsistence of the concept (Walker & Avant, 
1995). In the current literature, we have not been able to identify any empirical referents for 
measuring the effect, existence, or attributes of the decision partner concept. Currently, there are 
existing instruments of related concepts of perceived social support (PSS) using the family 
subscale (PSS-FA) and friends subscale (PSS-FR) (Glozah & Pevalin, 2017; Procidano & Heller, 
1983), and decisional support (Palmer-Wackerly, Krieger, & Rhodes, 2017).  
Discussion and Recommendations 
 Increasingly, a more inclusive philosophy of care that encompasses the importance of 
including the decision partner in health care decision making is needed.  This concept analysis 
may be a helpful first step in that direction.  The decision partner concept emphasizes the 
contribution that all stakeholders make to the patient’s decision-making, recognizing that each 
person involved is an expert in their own right.  From an ethical standpoint, the decision partner 
concept is supported by the principle of relationality that posits that human beings are 
intrinsically related to others and are members of communities (DuBois, 2007). In addition, 
understanding decision partners in healthcare decision-making has policy and practice 
implications. Incorporating decision partners could transform the way in which health services 
deliver collaborative and integrated care across systems; conducting evidence-based research that 
includes patients and decision partners as equal partners is important to fully understand 





value as well as a potential source of support or conflict in the decision-making process. 
Decision partners have the potential to recognize and acknowledge the choices that are most 
patient-centered by reflecting on the patient’s individual preferences and health outcomes and 
goals. As a result, their role could potentially improve patient adherence, compliance, and 
understanding about their health condition, which in turn, can result in better health outcomes, 
greater patient satisfaction (Joosten et al., 2008), as well as reduced health care costs (Chi, Wolff, 
Greer, & Dy, 2017; O’Connor, Bennett, Stacey, et al., 2009; Arterburn et al., 2012; Elwyn, 
Frosch, & Kobrin, 2015).   
There are key recommendations that may suggest ways to use and apply the decision 
partner concept in reshaping research, practice, and policy. First, a culture of research that 
involves patients and their decision partners must be embedded in academic curricula of health 
professionals and researchers and implemented in practice. In today’s health care, it is important 
for clinicians to not assume that patients make decisions in isolation. Therefore, it is imperative 
to develop and integrate decision partner engagement data and to direct attention to decision 
partners themselves for continuous improvement related to health care systems and community 
health-based programs. Furthermore, establishing and maintaining workforce capacity building 
that supports decision partner engagement is necessary to improve training and research efforts 
to improve decision partner engagement. Second, there must be attention to identifying ways to 
support patients who are able to identify a decision partner as well as those who cannot. 
Additionally, although patients may identify a decision partner, it is imperative that patients and 
decision partners still feel like they have access to members of the care team in order to optimize 





Third, future research is needed to measure and describe the relationship that decision 
partners have with patients, and clinicians, and with each other as they engage in decision-
making. These measures can support better understanding of the triadic relationships between 
patients, decision partners, and clinicians. Fourth, patient outcomes associated with decision 
partners should be examined including quality of life, healthcare utilization, treatment costs, 
effectiveness of care, satisfaction with care, medical errors, readmission rates, timeliness of care, 
integrated care and transitions of care, and mortality rates. These outcomes could be examined 
for differences when decision partners are engaged in decision making compared to when 
decision partners are absent. Measures and observations are needed to assess what patient 
characteristics predict or warrant the need for a decision partner, and interviews may help to 
understand reasons why some patients may not have a decision partner present while other 
patients do not. Fifth, future family communication interventions could explore ways to support 
patients and decision partners in communication surrounding shared illness experiences while 
respecting patients’ desire for their involvement. As patients’ health needs grow increasingly 
more complex, focusing on coordination and communication across all of a patient’s health care 
providers is even more crucial (McGinnis et al., 2013), as well as finding ways to incorporate 
decision partners. There is also a dearth of information related to how the role of decision 
partners vary across different cultures and geographic regions of the world that needs to continue 
to be explored. Sixth, decision partners need clinician support in order to be well-integrated in 
health care systems, community programs, policy reform, and public health initiatives related to 
healthcare decision making. Nurses are central to health care, working closely with patients, their 
support networks, and communities. This positions nurses well to acknowledge, advocate for, 





take an active role in policy and leadership not only in health care but in social policy that covers 
the gamut of human concerns (Grady & Hinshaw, 2017).   
Conclusions 
It is important to support and further explore dimensions of decision partners, describing 
how they may be deeply rooted within complex relational dynamics of patients that could 
potentially impact health care decision-making, satisfaction with care, health outcomes, 
treatment adherence, self-management practices, and sharing of information that helps clinicians 
better elicit, understand, and respect patient perspectives and preferences. With a dearth of 
knowledge in the current literature about decision partners, we aimed to explicitly define and 
describe their role and how their contributions may influence decisions. It is essential for nurses 
and other clinicians to identify and understand the role of decision partners in the context of 
health care decision-making, particularly as engagement of decision partners requires a shift in 
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Objective: To describe the relationships between Patient Factors (Decision Control Preferences, 
Age, Gender, Education, Marital Status, Race, Ethnicity), Clinical Trial Knowledge, Attitudes, 
and Beliefs, and Clinical Trial Participation (CTP).   
Methods: Adult cancer patients (n=82) were recruited from a parent study in the mid-Atlantic 
region of the United States. Patients screened as having an available clinical trial. Patient and 
decision partner demographics were collected, as well as cancer type, DCP, and patients’ clinical 
trial knowledge, attitudes, and beliefs. We performed descriptive statistics, bivariate analyses, 
and t-tests to assess for differences and associations.  Linear regression analyses were conducted 
to assess predictors of clinical trial knowledge, attitudes, and beliefs.  
Results: Among those who were offered a clinical trial (n=21), there were no statistically 
significant associations between race, caner type, gender, marital status, education, and CTP. 
Women tended to have higher scores related to knowledge, attitudes, and beliefs about clinical 
trials (p=0.022), even after controlling for education level and race. We did not have sufficient 
patients being offered clinical trial participation to be able to measure associations between DCP 
and CTP. 
Conclusion: Future studies should include larger and more diverse samples of participants who 
are offered a clinical trial to further understand the influences that decision partners have on 
clinical trial decision making.  
Practice Implications: Recruitment into cancer clinical trials can be successful, but there are 








Progress in prevention and control of cancer depends on research that identifies 
treatments that prevent or delay death caused by cancer or improve quality of life for patients 
living with cancer (Kanarek, Tsai, Metzger-Gaud, Damron, Guseynova, Klamerus, & Rudin, 
2010).  Clinical trials serve the overall population by determining the safety and efficacy of 
potential medical treatment (Jimenez, Zhang, Joffe, Nisson, Rivera, Mutchler, Lathan, Paulk, & 
Prigerson, 2013). Clinical trials can also be beneficial to participants themselves by giving them 
the opportunity to receive professional care and possibly to gain the benefit of new treatments 
before they are available outside of trials (Brown & Moyer, 2010). Enrollment of American 
cancer patients in clinical trials has remained modest despite significant progress in cancer care 
as well as the federal government’s own decades (Jimenez, Zhang, Joffe, Nisson, Rivera, 
Mutchler, Lathan, Paulk, & Prigerson, 2013). Low participation rates may stem from potential 
participants lacking an understanding of medical research studies, or it may result from a lack of 
vested interest in the condition or treatment under investigation if they are healthy or do not have 
personal experience with it (Brown & Moyer, 2010; Gillis et al., 2001).  In this article, we are 
exploring the social as well as demographic factors that may shape how individuals make 
decisions.  
1.1.  Specific Aims and Hypotheses 
Aim 1: To describe the relationships between Patient Factors (Decision Control Preferences, 
Age, Gender, Education, Marital Status, Race, Ethnicity), Clinical Trial Knowledge, Attitudes, 
and Beliefs, and Clinical Trial Participation.   
 





Lower educational attainment will be associated with decreased participation in a clinical trial.  
Younger age will be positively associated with clinical trial participation.  
Hypothesis 1.2: Knowledge, attitudes and beliefs will be associated with clinical trial 
participation.  
An increased clinical trial knowledge level and more positive attitudes and beliefs about clinical 
trials will be positively associated with a patient’s decision to participate in a clinical trial.   
Hypothesis 1.3: Educational level will be associated with decision control preference. Higher 
education level will be associated with a higher level of decisional control preference.  
Hypothesis 1.4 Decision control preferences will be associated with clinical trial participation.   
Preferences for a more deferred decision style will be positively associated with patient’s 
decision to participate in a clinical trial. 
2. Methods 
2.1. Setting and Recruitment 
Data collection occurred over a 24-month period from March 2016 to March 2018.  We 
recruited study participants were recruited from an outpatient clinic within a large 
comprehensive cancer center in the state of Maryland, within the mid-Atlantic region of the 
United States. Participants within this study had already consented and enrolled into a parent 
study, the EMPaCT Patient Navigation Study, which focused on evaluating the effectiveness of a 
patient navigation program to increase recruitment and retention into cancer clinical trials.  Since 
the patients were already consented and enrolled into the parent study, the inclusion criteria were 
similar to the inclusion criteria of the parent study. Inclusion criteria included that the patients 
had completed the Control Preference Scale, had a primary tumor cancer diagnosis (breast, 





available therapeutic cancer clinical trial as identified through medical record review and a 
specific content expert-derived screening algorithm created by research nurses and oncologists at 
the study site, had residency in the state of Maryland, aged 18 years and older, and were able to 
read, write and understand English. Exclusion criteria included primary residence outside of 
Maryland, medical record review did not identify an available therapeutic cancer clinical trial, 
and unable to read, write and understand English. All adults who are screened for an available 
therapeutic cancer clinical trial were contacted by phone prior to the scheduled medical oncology 
visit by either the author of this paper or the patient navigator of the parent study. The goal of 
this pre-visit call was to introduce and determine patient interest in participating in the parent 
study. Following the protocol of the EMPaCT parent study, participants received no financial 
compensation for their participation in completing the study.    
The parent study had sought and obtained full Institutional Review Board (IRB) approval 
from Johns Hopkins Medical Institutions (JHMI) (NA_00072282). For this study, addenda were 
incorporated and approved by the IRB to approve additional study measures obtained outside of 
the parent study. In order to find potential patients who may be eligible for cancer clinical trials, 
and therefore the parent study, the study team reviewed the electronic medical records. On the 
day of the oncology visit in the outpatient clinic, the patient navigator or first author of this paper 
approached the patient in the outpatient clinic waiting area with the goal of meeting with them 
prior to their encounter with the oncologist to discuss the study.  Patients had the opportunity ask 
questions and were informed that participation in the study was voluntary. A written informed 






All participants completed an initial assessment and questionnaires to ascertain 
sociodemographic data (age, race, ethnicity, gender, highest level of educational attainment, 
marital status), decision control preferences, as well as an assessment measuring clinical trial 
knowledge, attitudes, and beliefs. The outcome variable was the decision made about clinical 
trial participation (yes, no, not offered/delayed offer). The outcome variable was determined 
based on whether patients received an offer to participate in a therapeutic cancer clinical trial. 
Participants completed the questionnaires independently or with assistance from research team 
members.  
2.2.1. Sociodemographic Factors 
Patients reported their age, gender, highest level of educational attainment, marital status, 
race, and ethnicity. Sociodemographic factors are those modifiable and unmodifiable patient and 
decision partner characteristics that may influence the decision regarding cancer clinical trial 
decision-making. Sociodemographic factors are socially constructed and have been shown to be 
predictors or characteristics of cancer patients who participate in clinical trials.  The categories 
for gender included male and female. The categories for race were: African American or Black, 
White, Asian or Asian American, American Indian or Alaska Native, and Native Hawaiian or 
Pacific Islander, or Other.  The categories for ethnicity used in this study were Hispanic or 
Latino and non-Hispanic or Latino. Information was obtained through electronic medical records 
and self-reports by the patient.  The options for educational attainment included 8th grade or less, 
9th-11th grade, high school graduate, some college, community college/technical, bachelor’s 
degree, master’s degree, doctoral degree, and missing/unreported. The options for marital status 





missing/unreported. Information was obtained through electronic medical records and self-
reports by the patient. 
2.2.2. Cancer Type 
The cancer type was defined as the primary tumor site of the patient. Validated by our 
EPIC screening and medical record, these data regarding the specific cancer type was used in our 
analysis. Cancer types included breast, prostate, endometrial, multiple myeloma, ovarian, and 
head and neck 
2.2.3.   Clinical trial knowledge, attitudes, and beliefs assessment 
Study participants were asked about their knowledge, attitudes, and beliefs about clinical 
trials using the 18-item Clinical Trial Knowledge, Attitudes, and Beliefs Assessment.  
Participants responded to statements such as “The information gained from clinical trials may 
help a friend or family member”, “I think all patients who are eligible should be asked to take 
part in clinical trials”, “I would only take part in a clinical trial if I thought that my own health 
would benefit”.  The entire assessment can be in found in Appendix E. The survey has been 
shown to have a Cronbach alpha of 0.661. Responses were originally developed on a five-point 
Likert scale that ranged from 1(strongly agree) to 5 (strongly disagree). The assessment was 
reverse coded to have higher scores reflect having more knowledge and more positive attitudes 
and beliefs about clinical trials. After the reverse scoring, additive scale score ranges were could 
range from 49 to 70, and high scores indicate higher knowledge and more positive attitudes and 
beliefs about clinical trials.  
We decided to include this questionnaire in our study because research indicates that 
cancer patients who are offered or enrolled may have low levels of knowledge about clinical 





Chill, & Scott, 2004; Itoh et al., 1997). In general, research has shown knowledge deficits 
(Curbow, Fogarty, McDonnell, Chill, & Scott, 2004; Ellis & Butow, 1998). Cox (2000) 
conducted a series of four interviews with 55 patients with advanced cancer who were offered 
participation in Phase I or Phase II trials. Results indicated that only 16% of the patients could 
explain the purpose of the clinical trial they were offered. It has been shown that patients often 
turned down participation if the information about the clinical trial was harder to understand 
(Curbow, Fogarty, McDonnell, Chill, & Scott, 2004; Lovegrove, Rumsey, Harcourt, & 
Cawthorn, 2000). Moreover, with increasing numbers of studies on research ethics and a need to 
improve the recruitment of research subjects, the ability to measure attitudes toward biomedical 
research has become important (Rubright, Cary, Karlawish, & Kim, 2011).  
2.2.4.  Decision Control Preferences 
Decisional control is often used in the decision science literature to describe patients’ 
ability to play an active role in making decisions about their treatment (Adams & Drake, 2006; 
Ghane, Huynh, Andrews, Legg, Tabuenca, & Sweeny, 2014). It refers to one’s specific role in a 
treatment decision process rather than a broad approach to health care (Edwards & Elwyn, 206). 
Patients’ decision control preferences for decision partner involvement were measured using the 
Control Preferences Scale (CPS).  The original scale has been used and validated in several 
studies to assess the degree of control patients prefer over medical decisions with their doctors 
(Degner & Sloan, 1992).   
The question in the original scale was “How do you prefer to make medical decisions 
with your doctors? The response options from the original scale compared to the response 










Original Scale Modified Scale 
1 I make all medical decisions on 
my own 
 
I prefer to make the final decision about 
which treatment I chose 
2 I make the final decision myself 
only after considering my 
doctor's opinion 
I prefer to make the final decision about 
which treatment I will receive after 
seriously considering the opinion of my 
family/friends 
 
3 My doctors and I share decision 
making equally 
I prefer that my family/friends and I 
share responsibility for deciding which 
treatment I will receive 
 
4 My doctors make the final 
decision for me only after 
considering my opinion 
I prefer that my family/friends make the 
final decision about which treatment I 
will receive, after seriously considering 
my opinion 
 
5 My doctors make all medical 
decisions for me 
I prefer to leave all decisions regarding 
which treatment I will receive to my 
family/friends 
 
(Degner & Sloan, 1992; Chiu, Feuz, McMahan, Miao, & Sudore, 2016) 
 
There is also a subcomponent of the modified Control Preferences Scale, Part B, that 
evaluates patients’ preferences regarding whether their (1) doctor’s input weighs most heavily in 
decision-making; (2) My family/friends' input weighs most heavily; or (3) My doctor's input and 
my family/friends' input are equally important. To maintain a sufficient number of cases for 
statistical analysis per category, we grouped answer options in Part A into two categories that 
included high decision control preference and deferred decision style. Response 1 was coded to 
represent high decision control preference (high DCP). Responses 2, 3, 4, and 5 were grouped to 
reflect a deferred decision style for statistical analyses.  





The primary outcome measure for the study was clinical trial participation among the 
adult cancer patient-participants. Clinical trial participation was determined through medical 
record review and self-report from the participants in this study.  There were three different 
responses for this variable, including (1) yes, (2) no, (3) not offered/delayed offer.  
2.3 Data Analysis 
 Descriptive statistics were compared and used to summarize the sample and instrument 
characteristics. Prior to the main analysis, exploratory analysis was completed to examine the 
status of missing data as random or systematic and outliers.  Missing data were primarily 
associated with financial information, such as income and employment, as well as level of 
educational attainment and these missing data were not included in analysis. We performed mean 
imputation and pair-wise deletion to address missing data related to clinical trial knowledge, 
attitudes, and beliefs since many of the missing data were related to four participants randomly 
not answering one item on the 18-item scale. Data generated were reviewed and analyzed using 
the Chi Square tests or Fisher’s exact test as appropriate to examine associations between 
variables. In addition to assessing associations with decision control preferences for a subset of 
26 participants who completed the Control Preferences Scale, we also assessed how patients’ 
knowledge, attitudes, and beliefs about clinical trials differed by gender using t-tests and one-
way ANOVA. Due to the small number of patients offered a clinical trial at the time of our 
analysis, we were not able to perform logistic regression to examine predictors of the clinical 
trial participation.  Instead, we conducted exploratory analyses, including linear regression, to 
examine predictors of clinical trial knowledge, attitudes, and beliefs. A p-value < 0.05 was 







 Bivariate analyses were conducted to assess relationships between patient characteristics, 
decision control preferences, knowledge, attitudes, and beliefs about clinical trials, and clinical 
trial participation. Given the small percentage of decision partner data obtained (n=12), we were 
unable to include these data in our statistical analyses.  
3.1 Patient demographics, clinical status, decision control preferences, and composite score of 
clinical trial knowledge, attitudes, and beliefs 
Of the 82 participants, 51.2% (n=42) were male and the mean age +/- standard deviation 
(SD) was 60.55 +/- 12.017 years.  Most individuals (32.9%, n=27) were between the ages of 51-
60 years old. Of the participants, 73.2% (n=60) were married.  Comparison of clinical data 
indicated that nearly one third (32.9%, n=27) of the participants were diagnosed with prostate 
cancer, followed by 30.5% (n=25) diagnosed with breast cancer, 19.5% (n=16) diagnosed with 
multiple myeloma, 12.2% (n=10) diagnosed with head and neck cancer, and the remaining 4.9% 
(n=4) diagnosed with either ovarian cancer or endometrial cancer.  The sample included 53.7% 
(n=44) White, 36.6% (n=30) Black or African American, 7.3% (n=6) Asian or Asian American, 
and 2.4% (n=2) identified as Other. Additional demographic characteristics of the total 
participants are described below. This sample was also highly educated with 61% (n=50) 
reporting at least some college education among those who completed questionnaire information 
about their highest level of education completed. Less than 27% (n=7) of the participants who 
completed the Control Preferences Scale reported a preferred for a high level of decision control, 







Table 2. Descriptive Statistics: Demographic Characteristics of the Study Participants 
(N=82) 
 Cancer Patient Sample n 
(%) 






































Head and Neck 

















Highest Level of Education Completed  
9th – 11th Grade 
















Clinical Trial Knowledge, Attitudes, and Beliefs (Score can range 18-90) 
Mean Score (SD)  
Min Score (Lowest Reported) 









Decision Control Preferences (n=26) 








2) I prefer to make the final decision about which treatment I will 
receive after seriously considering the opinion of my family/friends 
3) I prefer that my family/friends and I share responsibility for deciding 
which treatment I will receive 
4) I prefer that my family/friends make the final decision about which 
treatment I will receive, after seriously considering my opinion 
5) I prefer to leave all decisions regarding which treatment I will receive 









3.2 Bivariate Analyses of Total Sample 
For the total sample (n=82), it was concluded that there was no statistically significant 
associations with clinical trial participation (yes, no, not offered/delayed offer) among race 
(p=0.999), ethnicity (p=0.999), gender (p=0.404), age (p=0.154), marital status (p=0.403), 
education (p=0.550), and CTKAB (p=0.422).  
Table 3. Bivariate Analyses: Demographic Characteristics of Patient Participants Grouped 
by Clinical Trial Participation Decision (N=82) 
 
 Clinical Trial Participation  
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         High school graduate and below 































Knowledge Attitudes and Beliefs 
about Clinical Trials (n=80) 
 0.422 
*p-value < or = 0.05 is statistically significant 
 
3.3 Bivariate Analyses of Participants Offered a Clinical Trial 
 
We conducted bivariate analyses of participants who were actually offered a clinical trial.  
We had similar results compared to the total sample data. The results show that the association 
between gender and clinical trial participation was not statistically significant (p=0.646). This 
was also true for age (p=0.656), education (p=0.999), race (p=0.999), and marital status (0.999) 
as none of these factors were found to be associated with the decision surrounding clinical trial 
participation. Though not statistically significant, we found that cancer type was potentially 
associated with clinical trial participation (p=0.107). Given the small number of participants who 
responded to the Control Preference Scale (n=26) and the limited number of individuals actually 
offered a clinical trial, we were unable to examine for any relationship with clinical trial 
participation. Additionally, marital status was found to have a statistically significant association 











Table 4. Bivariate Analyses:  Study Participants Offered a Clinical Trial (N=21) 
 
Clinical Trial Participation Decision (n=21) 
(percentages across row categories) Yes (total n=13) 
(n, %) 
No (total n=8) 
 (n, %) 
P 
Value 
Gender    
Male 9 (69.2%) 4 (30.8%)  
Female 4 (50%) 4 (50%) 
Age    
60 years of age and younger 5 (71.4%) 2 (28.6%)  
Over 60 years of age  8 (57.1%) 6 (42.9%) 
Race    
White 7 (63.6%) 4 (36.4%)  
Non-White 6 (60%) 4 (40%) 
Cancer Type    
Breast 2 (40%) 3 (60%)  
Prostate 6 (75%) 2 (25%) 
Multiple Myeloma 1 (25%) 3 (75%) 
Head and Neck 4 (100%) 0 (0%) 
Other 0 (0%) 0 (0%) 
Marital Status    
Married 11 (61.1%) 7(38.9%)  
Non-Married 2 (66.7%) 1 (33.3%) 
Education    
High school graduate and below 1 (50%) 1 (50%)  
Some college or higher 9 (60%) 6 (40%) 
Knowledge, Attitudes, and Beliefs 
about Clinical Trials (n=20) 
  
    
Decision Control Preference (n=26) 
 High level of decision 
control (total n=7) 
(n, %) 
Deferred decision 
style (total n=19) 
 (n, %) 
P 
Value 
Gender    
Male 5 (35.7%) 9 (64.3%)  
Female 2 (16.7%) 10 (83.3%) 
Age    
60 years of age and younger 4 (26.7%) 11 (73.3%)  
Over 60 years of age  3 (27.3%) 8 (72.7%) 
Race    
White 3 (23.1%) 10 (76.9%)  
Non-White 4 (30.8%) 9 (69.2%) 
Cancer Type    
Breast 2 (33.3%) 4 (66.7%)  
















Multiple Myeloma 2 (28.6%) 5 (71.4%) 
Head and Neck 1 (25%) 3 (75%) 
Other 0 (0%) 2 (100%) 
Marital Status    
Married 2 (11.1%) 16 (88.9%)  
Non-Married 5 (62.5%) 3 (37.5%) 
Education (n=19)    
High school graduate and below 3 (75%) 1 (25%)  
Some college or higher 2 (18.8%) 13 (81.3%) 
*p-value < or = 0.05 is statistically significant 
 
 
3.4 Exploratory Analysis 
 
Exploratory analyses, including t-tests and linear regression with predictor variables of 
knowledge, beliefs, and attitudes about clinical trials were conducted. There were no statistically 
significant differences in knowledge, attitudes, and beliefs about clinical trial by decision control 
preference groups (p=0.880). We found that race, gender, and education were strong predictors 
of CTKAB. White participants tended to have a higher mean score for knowledge attitudes, and 
beliefs about clinical trials (67.28, n=43), than non-white participants (61.24, n=37). Patients 
with some college education also tended to have higher scores (67.47, n=49) related to 
knowledge, attitudes, and beliefs about clinical trials compared to those with high school 
graduate and below (57.73, n=15). Women tended to have higher knowledge, and more positive 
attitudes and beliefs about clinical trials than men by 4 points on average (p=0.022), even after 
controlling for education level (p=0.000) and race (p=0.055). Also, white participants tended to 
have a higher mean score for knowledge, attitudes, and beliefs about clinical trials (mean score 
of 67.28), than non-white participants (mean score of 61.24), with differences at the edge of 
significance after controlling for gender and education (p=0.055). Those with some college 







trials (p=0.000) by 8 points on average compared to those with a high school degree and below 
after controlling for race and gender. 















High school and below (Ref group) 






 Table 6 also describes the demographic characteristics for the decision partners, including 
gender, age, race, ethnicity, and relationship to patient.  
 
Table 6. Demographic Characteristics of Decision Partners 
 
Study ID Gender Age Race Ethnicity Relationship 
to Patient 
058DP1 Female 55 White Non-Hispanic 
 
Wife 




061DP1 Male 69 White Non-Hispanic 
 
Husband 






066DP1 Male  68 White Non-Hispanic 
 
Husband 
071DP1 Female  47 White Non-Hispanic 
 
Husband 



















078DP1 Male  49 White Non-Hispanic 
 
Husband 












4. Discussion and Conclusion 
4.1 Discussion 
 Research on decision control preferences has repeatedly shown that a shared approach to 
control decision making in healthcare is preferred by the largest group of patients (Schuler et al., 
2017). Our results were similar, with the majority of patient-participants (83%) reporting a more 
deferred decision style. This emphasizes the notion of assessing and addressing patient’s 
decisional control preferences related to involving decision partners in their clinical trial 
decision-making process.  Patients can be supported if they wish to have a friend, family 
member, neighbor, significant other, or other self-identified individual serve as decision partner.   
Furthermore, cancer patients’ beliefs and attitudes related to clinical trials and research 
have been shown to be important personal factors association with clinical trial participation 
(Bell & Balneaves, 2015). In an integrative review by Bell & Balneaves (2015), it was reported 
that many studies (36%) found patients’ positive beliefs about the benefits of clinical trials were 
associated with their decision to participate in cancer research, and these beliefs included a desire 
to help others, perceived personal benefit, and hope for a cure (Bell & Balneaves, 2015; Lara, 
Higdon, Lim, Kwan, Tanaka, Lau, Wun, Welborn, Meyers, Christensen, O’Donnell, Richman, 





Emanuel, 2006; Avis, Smith, Link, Hortobagyi, Rivera, 2006; Cantania, De Pas, Goldhirsch, 
Radice, Adamoli, Medici, Verri, Marenghi, de Braud, & Nole, 2008; Catt, Langridge, 
Fallowfield, Talbot, & Jenkins, 2011; Davison, So, Goldenberg, Berkowitz, & Gleave, 2007; 
Truong, Weeks, Cook, & Joffe, 2011; Wang, Tsai, Chen, & Tsay, 2011). Due to the limitations 
in clinical trials being offered to study patients, we were underpowered to detect any statistical 
significance in associations between knowledge, attitudes, and beliefs about clinical trials and 
clinical trial participation. In the larger sample of participants that included those who were not 
offered or received a delayed offer, we found an association (p=0.126) with knowledge, 
attitudes, and beliefs about clinical trials, compared to those who were actually offered 
(p=0.566). Given this difference in p-values, future work is needed to further explore potential 
provider bias and whether or not patients were not offered due to physicians’ perceptions and 
assumptions about a patient’s knowledge, attitudes, and beliefs or for clinical ineligibility.   
We found no differences in mean age among all three groups: those who were offered 
and said yes, those who were offered and said no, and those who were not offered or received a 
delayed offer. We also recognize that 17 participants refused to answer or did not complete 
survey information regarding education level. Data about education attainment is critical to 
understand decision making and preferences for decision partner involvement. Results from 
exploratory linear regression tests and t-tests found that women tended to have higher 
knowledge, and more positive attitudes and beliefs about clinical trials than men by 4 points on 
average (p=0.022), even after controlling for education level (p=0.000) and race (p=0.055). 
There were no statistically significant differences in knowledge, attitudes, and beliefs about 
clinical trial by decision control preference groups (p=0.880).  Also, white participants tended to 





of 67.28), than non-white participants (mean score of 61.24), with differences at the edge of 
significance after controlling for gender and education (p=0.055). Those with some college 
education tended to have higher scores related to knowledge, attitudes, and beliefs about clinical 
trials (p=0.000) by 8 points on average compared to those with a high school degree and below 
after controlling for race and gender. This finding enforces the need to assess health literacy 
levels and target efforts appropriately to ensure that minority populations have adequate 
information regarding the importance of clinical trials, as well as improving positive perceptions 
about research in communities.  
4.2. Strengths and Limitations 
 We recognize that these analyses had several limitations. First, it is important 
acknowledge that the sample and measures used for this study were limited to those included in 
the parent study.  This limited our ability to incorporate other measures and add more 
participants into the study design. Second, this study included a relatively limited sample.  
Statistical power was limited, so possible associations between decision control preferences, 
gender, race, ethnicity, age, cancer type, marital status, clinical trial participation, and 
knowledge, attitudes, beliefs about clinical trials, and further clinical characteristics may have 
been missed and will require drawing on larger sample sizes for future studies to assess for 
statistically significance.  Third, due to the design of the parent study, we were restricted in 
recruiting patients who were residents of the catchment area of Maryland rather than also 
targeting patients who lived outside the state. We were also limited to selected cancer types. 
Findings may be different for patients who lived in other geographic regions and with other 
cancer types. Fourth, our study was restricted to participants who spoke and understood English. 





were excluded from the study.  However, within the Sidney Kimmel Comprehensive Cancer 
Center, this does not represent a large group of patients being excluded as our largest minority 
population is African American.  Therefore, we can draw limited conclusions regarding their 
decision-making about clinical trial participation. Due to the small amount of data about decision 
partners, we were not able to examine statistical associations with patient data. Future studies 
should obtain these data for decision partner to be able to draw fuller conclusions. Fifth, the 
respondents of the questionnaires consisted of individuals who were willing to take part in the 
study, potentially creating bias. The study may have drawn respondents who were particularly 
interested in cancer, clinical trials, or decision control preferences for decision partner 
involvement in treatment decision-making. Furthermore, future studies should measure patients’ 
intent or willingness to participate in a clinical trial needs and compare those findings with actual 
clinical trial offer and actual participation. Sixth, there may be potential social desirability bias in 
how participants completed the questionnaire about knowledge, attitudes, and beliefs about 
clinical trials.  More psychometric testing is needed to accurately and objectively measure 
understanding and perceptions about clinical trials. Seventh, there may have been bias in how 
potential participants were screened using the algorithm due to random error. Lastly, this was a 
highly educated sample, with 61% of those reported to have at least some college education. This 
could create potential bias in their preferences to involve decision partners in decision making 
and what they knew about clinical trials.  
 Despite the limitations, there were several strengths of this study. First, the study sample 
was racial and ethnically diverse, and reflected the ethnic make-up of the region where the study 
was conducted. Second, the sample included a nearly equal number of males and females with a 





information about barriers to clinical trial decision making and participation, given the high 
number of participants who were ineligible (75%, n=61). These data helped to provide insight 
about a clinical trial enrollment and future recruitment and retention needs of patients.     
4.3   Future Research  
There is a need for more diverse study samples and research staff members to reflect the 
populations they serve. Decision control preferences as well as knowledge, attitudes, and beliefs 
about clinical trials may be different across racial/ethnic groups. Large studies are also needed to 
further stratify by decision control preferences, cancer type and stage, and education levels to 
examine associations with clinical trial decisions. 
4.4   Practice Implications 
Healthcare providers will need to undergo dedicated training to learn how to incorporate 
information about patients’ decision control preferences into care and decision making. There is 
also a need for accurate electronic medical record reporting of both disease stage and clinical 
trial discussions that occur between clinicians and patients to better identify gaps in screening 
and eligibility. Furthermore, rather than simply asking the patient “do you understand?”, patients 
should be asked to explain their understanding of the proposed clinical trial, and offered time to 
think about the information and to discuss this with others (Jefford et al., 2010). Cancer patients 
make difficult treatment decisions, so it is important to assess their decision control preferences 
at the time of diagnosis and then intermittently throughout the course of illness. Additionally, a 
question prompt list (QPL) would be a valuable aid for patients facing difficult treatment 
decisions. QPLs consist of a written sample of questions that have demonstrated a significant 
promise in aiding doctor-patient communication and promote patient question asking (Brown, 
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This exploratory descriptive study explores the process of decision making about clinical 
trial participation among persons with high levels of decision control preferences and those with 
a deferred decision style. We interviewed 12 adult outpatient cancer patients and 12 decision 
partners to gain their experiences and perspectives about clinical trial decision-making and learn 
about the role of decision partners in decision-making.  Patients were recruited from a sample of 
individuals who were already enrolled in a parent study and decision partners were selected by 
patients.  We used the process of inductive analysis to conceptualize codes into themes. Most of 
the patients (83%) reported a deferred decision style and 58% of the total sample was non-White 
and 54% female. Themes included: 1) Having the freedom to choose; 2) Getting the most insight 
about clinical trials; 3) Relationship building...Trusting someone in the process; and 4) Realizing 

















Clinical trials are critical to advances in the understanding and treatment of cancer (Joffe, 
Cook, Cleary, Clark, & Weeks).  Clinical trials are necessary for the improvement of patient care 
as they help to confirm the efficacy and safety of novel cancer treatments and in so doing, 
contribute to a solid evidence base on which practitioners and patients can make informed 
treatment decisions (Bell & Balneaves, 2015). Unlike in other diseases (Christofides, Dobson, 
Solomon, Waters, & O’Doherty, 2016), individuals with cancer heavily depend on clinical trials 
as a way to fight against their disease with the hope of survival and cure. Other cancer patients 
decide to participate for altruistic reasons to help future cancer patients (Truong, Weeks, Cook, 
& Joffe, 2011). However, despite its role in advances, clinical trials among adult cancer patients 
is currently as low as 3-5% (Wang, Tsai, Chen, & Tsay, 2011; Brown, Cadet, Houlihan, 
Thomson, Pratt, Sullivan, & Siminoff, 2013). Lack of participation compromises the success of 
clinical trials and squanders an opportunity for improving patient outcomes (Bell & Balneaves, 
2015). Clinical trial participation may involve unknown risks and benefits, and the decision-
making process to enroll in a study may be overwhelming and confusing for patients. Clinical 
trials are often presented near the time of a new diagnosis when patients are particularly 
emotionally, physically, and mentally vulnerable (Thorne et al., 2013; Rutten, Arora, Bakos, 
Aziz, & Rowland, 2005), taking more physical and mental energy than patients can afford 
(Butow, Maclean, Dunn, Tattersall, & Boyer, 1997).  Additionally, discussing complex treatment 
decisions, such as clinical trial participation, may result in increased patient distress and reduced 
ability to focus on and process critical information (Chen, Rossignac-Milon, & Higgins, 2018; 





In general, the decision of selecting a specific cancer treatment can be difficult and 
anxiety-producing and the hardship of decision making is even greater when the options include 
clinical trials. Moreover, illness is a biological and social process. A cancer diagnosis and 
subsequent treatment decisions affect a person’s entire social network, from family, to friends, to 
peers and colleagues. In an effort to bolster coping support and to receive assistance with 
treatment decision making, patients with cancer often to loved ones as sources of support when 
considering information about their diagnosis and treatment options including clinical trials. 
Although, families and friends are recognized as engaging in cancer care and treatment, there is a 
knowledge gap in understanding the way in which those relationships influence the patient’s 
decision-making specifically about clinical trial participation.  
Research that explores the clinical trial decision-making tends to focus on the decision-
making process of only the patient, neglecting the role that decision partners may have in the 
process. For this article, we have defined decision partners as family or friends who are engaged 
in decision-making about clinical trial participation with the patient and serve as trusted sources 
of support (Wenzel et al., 2015). Rather than assuming that patients make decisions in isolation, 
it is imperative to recognize the importance of social circumstances and significant relationships 
on individuals’ self-determination that may impact decision-making (Bell & Balneaves, 2015).  
The appreciation of patients’ preferences regarding participation in decision making is crucial in 
order to be able to individualize disclosure of information and patient involvement (Schuler, 
Schildmann, Trautmann, Hentschel, Hornemann, Rentsch, Ehninger, & Schmitt, 2017). This 
importance particularly applies to oncology, not only because the identification of patients’ 
preferences for information and control is important to avoid the often-occurring conflicts 





In marked contrast to the relatively well-developed body of quantitative literature on 
factors related to clinical trial accrual, qualitative research exploring the clinical trial decision-
making processes of cancer patients has been minimal, with only 15 studies having been 
conducted to date (Bell & Balneaves, 2015). The degree to which family members influenced 
patients’ choices for the patients’ own good (versus the family’s good), how they were involved 
in the decision-making process, and patients’ preferences with regard to the involvement of their 
family in clinical trial decisions, however, remained largely unexplored (Bell & Balneaves, 
2015). We also know that physicians often make assumptions about patients’ preferences for 
decisional control that may be inaccurate (Ghane, Huynh, Andrews, Legg, Tabuenca, & Sweeny, 
2014).  
Purpose 
 Therefore, an exploratory descriptive design was used to elicit first-hand descriptions of 
patient and decision partner experiences and perspectives about clinical trial decision-making. 
We explored how adult outpatient cancer patients approach clinical trial decision-making based 
on their varying levels of decisional control preferences for decision partner involvement.  We 
included patients who reported high levels of decisional control preferences (DCP) and those 
persons with a deferred decision style as well as included decision partners, as selected by the 
patients, to gain their experiences and perspectives about being involved in clinical trial decision-
making.  
Methods 
Setting and Recruitment 
Study participants were recruited from a large comprehensive cancer center in the mid-





partners who the patients self-reported. We selected patients who decided to participate in a 
cancer clinical trial, not participate in a cancer clinical trial, as well as those who were not 
offered a clinical trial at the initial clinic visit when baseline data were being collected for the 
parent study but who were screened to have an available clinical trial. Patients that we recruited 
for this study were already consented and enrolled into a parent study, the EMPaCT Patient 
Navigation Study, which focused on evaluating the effectiveness of a patient navigation program 
to increase recruitment and retention into cancer clinical trials.   
Since the patients were already consented and enrolled into the parent study, the inclusion 
criteria were similar to the inclusion criteria of the parent study. Inclusion criteria included that 
the patients had completed the Control Preference Scale, had a primary tumor cancer diagnosis 
(breast, prostate, multiple myeloma, ovarian, endometrial, head and neck), were screened to have 
an available therapeutic cancer clinical trial as identified through medical record review, had 
residency in the state of Maryland, aged 18 years or older, and were able to read, write and 
understand English. The inclusion criteria for decision partners included being 18 years or older, 
and who were able to read, write and understand English, and identified as a decision partner by 
the patient. Each participant received up to $30 and a parking voucher as needed for their 
participation. We approached or made a phone call to 19 patients about participating in an 
interview about the decision-making process regarding clinical trial participation and their 
perceptions about involving decision partners in that process. Two patients were deceased at the 
time when the interviews were conducted, four patients never returned our phone calls for 
participation, two patients were approached in clinic after being introduced to the study over the 





phone call was made to one patient who deferred to a later time and never returned follow-up 
calls.  
Methodology 
We interviewed patients from a variety of reported scores on the modified version of the 
Control Preference Scale that examined decision control preferences for decision partner 
involvement in decision making.  We aimed to apply maximal variation sampling to allow for a 
fuller understanding of how patients, from a range of decision control preferences, make 
decisions and how they prefer to involve decision partners and others in decision making.  The 
Control Preference Scale (CPS) was developed by Degner and colleagues (Degner, Sloan, 
Venkatesh, 1997).  Participants were selected for interviews based on whether the patients 
completed the CPS. On this scale, patients could pick one statement out of five that best 
describes their preferred involvement in medical decision making. The ranges of options are 
described below in Table 1.  
Table 1. Grouped Categories for Patients’ Decision Control Preferences  
 




“I prefer to make the 
final decision about 
which treatment I will 
receive”  
 
“I prefer to make the final decision about my treatment after 
seriously considering the opinion of my family/friends”  
 
“I prefer that my family/friends and I share responsibility for 
deciding which treatment is best for me”  
 
“I prefer that my family/friends make the final decision about 
which treatment I will receive, but seriously consider my 
opinion”  
 
I prefer to leave all decisions regarding my treatment to my 
family/friends”  
 
*Grouped decision control preferences are denoted as the patient’s decision control preference 






  There was also a subcomponent of the Control Preferences Scale that evaluated patients’ 
preferences regarding whether their (1) doctor’s input weighs most heavily in decision-making; 
(2) My family/friends' input weighs most heavily; or (3) My doctor's input and my 
family/friends' input are equally important.  
A semi-structured interview guide was developed by the study team through formative 
exploration of the available literature, clinical experiences and input, and informal peer and 
expert review. Data collection occurred over a four-month period from November 2017 to March 
2018. Audio-recorded telephone, video, or face-to-face interviews were conducted by a single 
interviewer, the first author, who had clinical and research experiences working with adult 
cancer patients and families as a certified oncology nurse.  Semi-structured interviews were 
chosen as the most appropriate method for our study, as the alternatives, structured or 
unstructured interviews, would offer little opportunity for free expression (Newell, 1994) or risk 
losing control of the focus of the conversation respectively (Yan & Wildemuth, 2009). We 
scheduled interview dates, times, and location based on participant preferences and the 
availability of private interview space within the clinic. Participants had the option to choose to 
participate in individual interviews, dyadic interviews, or separate interviews with their decision 
partner present if the patient had identified a decision partner.  The interviewing options were 
provided to maximize the setting in which the participants would feel most comfortable. The 
interviews were, on average, approximately 25 minutes in length, ranging from 16 minutes to 1 








Table 2. Selected Interview Questions 
Patient Interview Questions 
 
Decision Partner Interview Questions 
 
Topic: Patients’ preferences to involve decision partners in health-related decisions 
Related to your cancer care, how do you like to 
include people in health-related decisions? 
In what ways do you think families or decision 
partners should and can be involved in 
decision making? 
 
Topic: Knowledge and Perceptions about Clinical Trials 
What are your ideas about participating in 
research? When you hear the term clinical 
trial, what comes to mind? 
 
Were you offered to participate in a clinical 
trial? If so, please tell me some of the reasons 
why you decided to participate or not 
participate?  
 
When you hear the term clinical trial, what 
comes to mind? 
 
What do you think about if your loved one 
were to be invited to participate in a clinical 
trial? 
 
What do you think [patient pseudonym] knows 
about clinical trials? 
 
Topic: Timing to Discuss Clinical Trials 
When do you think is an ideal time to discuss 
clinical trials?  
When do you think is an ideal time to discuss 
clinical trials? 
 
Topic: Decision partner role in clinical trial decisions 
Who is important to discuss a clinical trial 
decision with? 
 
What role does [decision partner pseudonym] 
play in helping you reach a decision about 
participating in a clinical trial? 
 
Could you tell me about how you are involved 
in the decision related to whether or not 
[patient pseudonym] participates in a clinical 
trial? 
 
Topic: Recommendations to improve clinical trial decision-making. 
What would make the process of deciding 
whether or not to take part in a clinical trial 
easier or better? 
  
What would make the process of deciding 
whether or not to take part in a clinical trial 
easier or better? 
 
Ethics 
Ethical approval for this study was obtained from the Johns Hopkins Medicine 
Institutional Review Board (JHM IRB) (NA_00072282). Prior to the start of each interview, oral 





telephone, or video, depending on which method was most convenient for the participant. 
Consenting, data recording, and interview transcription procedures were conducted in 
accordance with JHM IRB policies. To provide privacy and confidentiality, all participants were 
advised that their responses would remain anonymous and that all individual identifiers would be 
removed from the data. Names in this manuscript have been replaced with a pseudonym. Only 
those details interpreted as necessary to understand the findings have been reported.   
Data Analysis  
The final sample size was determined by the number of interviews required to reach 
informational redundancy, and data saturation was determined after conferring with data coders 
and consulting qualitative research mentors. We audio recorded and professionally transcribed 
verbatim the interviews, checked for accuracy in the transcription, de-identified prior to analysis, 
and then uploaded the transcripts into Nvivo Version 11 to organize data and facilitate analysis. 
We analyzed the data using hermeneutic phenomenological analysis, which involves the 
reflection on the data, explication of themes, and discernment of patterns to fully understand the 
essence of the lived experience for participants, with a focus on their shared experience and 
perspectives (Bynum & Varpio, 2018). Two first and second author were involved in the line-by-
line review of each interview and performed the first phase of analysis independently. 
Transcripts were first read several times independently by the first and second authors to allow 
for general impressions for the content to develop into categories and preliminary codes. Pre-
coding, also known as first-level coding, was the first step of the analytical process that included 
circling, highlighting, underlining, or bolding, rich or significant quotes or passages that were 
particularly notable (Saldana, 2016). The data were then individually coded and analyzed by the 





of the coded segments throughout the coding process to verify the coding scheme and inter-rater 
agreement.   
Next, the process of inductive analysis continued as categories emerged from coded 
segments, a process known as second-level coding (Saldana, 2016). We then compared second-
level codes of data to conceptualize the codes into themes that describe the meaning of 
experiences related to the process of decision-making about clinical trial participation. Once a 
codebook was developed, all codes were reviewed and collapsed into categories and themes 
through an iterative process of classifying, comparing, grouping, refining and data reduction 
(Sandelowski, 2000; Bakitas, Dionne-Odom, Jackson, Frost, Bishop, & Li, 2016).  Themes were 
defined as clusters of linked categories that convey similar meaning. The primary author returned 
often to the audio recordings and transcripts through a recursive process to verify interpretations 
and applications of the codes and themes. Once preliminary findings were decided on between 
the first and second author, the findings were shared with the remaining authors, who were 
content and methods experts and peers. Any discrepancies between the first and second author 
were also brought to this study team and a final decision was made after further discussion that 
included a re-evaluation and comparison of the coded data. After receiving input from the study 
team, findings were refined, as presented below.  
We enhanced study trustworthiness, including credibility, dependability, and 
transferability (Graneheim & Lundman, 2004) via four strategies. First, we maintained an audit 
trail of study activities, including field notes from each interview. Methodological and analytical 
memos were also used for documenting decisions related to refining and defining codes, 
patterns, or categories as a way to document communications from the research team. This 





participants. Second, the primary interviewer had expertise in both clinical practice and research 
of pediatric and adult cancer patients, and the peer and expert reviewers had experienced with 
qualitative analyses focusing on chronic illnesses and family research. Third, at each stage, 
coding was completed by at least two researchers, and discrepancies were discussed and 
clarified. Fourth, dependability was obtained by having the same researcher (first author) 
conduct all interviews over a relatively short period of time (4 months). Overall, data analysis 
was an iterative process to support thematic analysis (Braun & Clark, 2006) that involved 
discussions of the analytic decisions with members of the research team until a consensus was 
reached.   
Results 
Demographics and Participant Characteristics 
 Patient interviews were undertaken with 24 adult cancer patients (n=12) and decision 
partners (n=12) who consented to participate in the study. We calculated descriptive statistics 
with SPSS Statistical Software Premium GradPack 25 for Windows. Total participants were 
mostly female (54%, n=24) and mostly white (42%, n=10), followed by 38% (n=9) African 
American/Black. The average age and standard deviation (SD) of an adult cancer patient who 
participated in the interviews was 59.8 years (10.4), with a range of 42 to 74 years.  The average 
age and SD of a decision partner was 53.4 years (13.1), with a range of 32 to 69 years. Most 
(58%, n=7) of the decision partners were spouses of the patients, 17% (n=2) were either children 
or grandchildren, 17% (n=2) were either friends or colleagues, and the remaining decision 
partner (8%, n=1) was identified as a cousin.  Most of the adult cancer patients had a primary 
cancer diagnosis of breast cancer (25%, n=3) or prostate cancer (25%, n=3), followed by 





ovarian cancer (8%, n=1). Of the twelve patients, 50% (n=6) had been offered a cancer clinical 
trial or received a delayed offer pending prerequisite medical information. Furthermore, over half 
of the patients (58%, n=7) reported to prefer making final decisions about treatment after 
seriously considering the opinion of family or friends, rather than equally sharing in the decision-
making process with family or friends (25%, n=3) or making the final decision without the input 
of others (17%, n=2).  A full description of the characteristics of the participants can be found in 
Table 3.   
Table 3. Demographic Characteristics of the Qualitative Study Participants (N=24) 
 














































Clinical Characteristics of the Patient 












Time Since Cancer Diagnosis  
< 1 year ago 
1-2 years ago 





Social and Decisional Characteristics of the Patient 








           Yes 
            No 
10 (83%) 
2 (17%) 








Decision Partner’s Relationship to Patient 
         Spouse 
         Child or grandchild 







Decisional Control Preferences 
“I prefer to make the final decision about my 
treatment after seriously considering the 
opinion of my family/friends.” (Deferred) 
 
“I prefer that my family/friends and I share 
responsibility for deciding which treatment is 
best for me.” (Deferred) 
 
“I prefer to make the final decision about 














 Combined interview analysis categorized the participant data into five themes that were 
related to the decision-making process about clinical trial participation.   
 Theme 1: Having the freedom to choose 
Theme 2: Getting the most insight about clinical trials 
 
Theme 3: Building relationships...Trusting someone in the process 
 
Theme 4: Realizing readiness and context 
 
Theme 1: Having the Freedom to Choose 
  The first theme that emerged from the data was “having the freedom to choose”. When 
discussing clinical trial decision making, both patients and decision partners discussed the 





which to choose, having access to care that could include clinical trials, demonstrating decision-
making self-efficacy, maintaining a sense of autonomy, and that having the freedom to choose 
was based on being comfortable in gathering and processing information about clinical trials 
from either the patients’ or decision partners’ standpoint.  
 Having multiple options. A core component of decision-making is identifying that there 
is more than one option from which to choose among others. In the interviews, patients and 
decision partners expressed their recognition that a clinical trial was only one treatment option 
from which they could choose, even if the other options included standard therapy, a risky 
procedure, or waiting to treat. One decision partner noted that her mother, who was enrolled in a 
clinical trial, was given an option to undergo a risky procedure that would alter her life 
substantially or the clinical trial. She explained that: “Yeah, the fact that we'd even consider that 
as an option-- you would have to have tried everything possible before you could even consider 
that…so I don't really call that an option, but that's what she was offered.” (081DP1, 55 yo, 
female, patient with deferred DCP). 
 Access to care. Another aspect of “having the freedom to choose” was about access to 
care, specifically regarding access to clinical trials. All participants lived in the same state, an 
area that has numerous health care systems and options for care. Some lived near prominent 
health care systems that conducted many clinical trials while others lived farther away and 
shared their care with the local community hospital with more limited treatment or trial options. 
Regardless of where they lived, participants had access to various health care systems, and many 
of them deliberately chose the cancer center where this study was conducted because of its 
reputation, expansive treatment options including clinical trials, and renowned doctors. In the 





sense of “not wanting to settle” for suboptimal care: “I felt that I wanted to come where I could 
get the best treatment.” (057P, 65 yo, male, high DCP).  They explained that if the clinical trial 
was the best hope for a cure and best treatment option for them, they would be open to 
participating. Therefore, having the freedom to choose involved having access to care that may 
include clinical trial was regarded as important in the decision-making process, regardless of 
their decision control preferences, because some participants deliberately sought out research-
intensive health care systems that would likely offer clinical trials. One patient, a male with a 
deferred decision style who was enrolled in a clinical trial, said that “we always feel very 
thankful to have [the cancer center] as a 10-minute ride from our house to have some of the best 
doctors and some of the best people working research on these diseases so readily available to 
me.” (058P, 55 yo, male, deferred DCP).  For another clinical trial-enrolled patient who lived 
more than an hour away from the cancer center, her decision partner shared that since the patient 
could not get to the appointments herself, the patient’s two decision partners “work together as a 
team...it took all three of us because she can’t get to herself to the appointments.” (081DP1, 55 
yo, female, patient with deferred DCP). The other decision partner explained that “because you 
needed a commitment…everybody needed to be on board.” (081DP2, 68 yo, female, patient with 
deferred DCP).  In this specific context, the patient and decision partners knew that having 
access to care and to the clinical trial influenced their perceptions about having the freedom to 
choose about clinical trial participation.    
Demonstrating decision-making self-efficacy. Within the theme of “having the freedom 
to choose” emerged an additional subtheme related to self-efficacy in decision-making or the 
confidence to make decisions.  Decision-making self-efficacy became evident as a trait that 





decision style expressed trust and assurance in their decision partners’ confidence and ability to 
assist in decision-making about clinical trials, even if the patients themselves lacked confidence 
or seemed unsure of their ability to make that decision. Similarly, one patient with a high DCP, 
stated that they were more focused on making the final decision about clinical trial participation 
after gathering information by reading articles, pamphlets, and searching on the Internet, without 
necessarily asking for the input of others.  
“I do have research skills and I had research different providers-- I researched their 
backgrounds, their educational history. I actually consider myself to be quite savvy as it 
pertains to that.” (057P, 65 yo, male, high DCP) 
 
Among participants, having confidence in their ability to make this difficult decision was 
important because there were many options and different people had different opinions about 
what was best. More specifically, making decisions about clinical trial participation can be a 
process of uncertainty because there are many unknowns. Therefore, exhibiting traits of self-
efficacy in decision-making, for either decision partners or patients, is necessary as one decides 
about clinical trial participation because there are high-stakes consequences involved.  
 For one patient (058P, 55 yo, male, deferred DCP) who was diagnosed with cancer a 
second time, his wife was his decision partner. She shared her approach in helping her husband 
decide about clinical trial participation, exhibiting confidence, even in the midst of uncertainty.   
“We looked at what they’d already seen, what had already happened with those two drugs 
or that, whatever-- we did a lot of research to see if we thought that would work for him. It 
was like a here-we-go-again type thing.  We knew…Well, we weren’t sure…so we had to 
make a decision based on what we knew at that moment.”  (058DP1, 54 yo, female, patient 
with deferred DCP) 
 
 Similarly, another decision partner, a husband of a patient with previous history of 
multiple cancers, asserted confidence in decision-making:   
 “I mean, <chuckles> first of all, it's like choose your own adventure. Right? If you go down 





best way you can present it is to say what are the odds for what the best case scenarios are 
going forward? You know, in choose your own adventure, you just basically click on the 
page and say this is where it's going to go, right?” (076DP1, 43 yo, male, patient with 
deferred DCP) 
 
 Maintaining a sense of autonomy. Decision partners and patients both expressed the 
importance of having the patient maintain a sense of autonomy in clinical trial decision-making, 
despite their decision control preferences. Decision partners expressed the idea of respecting 
patient autonomy in decision making, given the complex nature of the decision. Although her 
doctor discussed treatment options, one patient noted that “I went and I went looking... you need 
to be comfortable and trust your doctor. But you need to ask questions too and you need to go in 
with your questions ready...we’re just curious people and we’re not afraid to ask questions.” 
(061P, 58 yo, female, deferred DCP). Many participants also expressed the importance of having 
the freedom to choose who was involved in decision-making, often limiting to a small network of 
individuals in the process in order to maintain a sense of autonomy and privacy. Children or 
extended family were usually made aware of the decision but not necessarily involved in the 
process. It was described by one patient that: “Sometimes family can be very helpful, sometimes 
not so much. Every case is different” (061P, 58yo, female, deferred DCP). Another patient 
stated:  
“Certainly they [family] could disagree with you and then you thought you had the right 
decision and be afraid to say I'm doing what I want to <laughs>, I feel like that could be a 
challenge.” (066P, 63 yo, female, deferred DCP). 
 
 Comfort in gathering and processing information.  The theme having the freedom to 
choose is also about the comfort level of the individuals to be able to gather and process 
information about clinical trials. From the interviews, it was revealed that if participants did not 





have the freedom to choose was significantly impacted because they were not able to ask 
questions, unsure of what was being discussed, and could not adequately receive and process the 
information to make an informed decision. One decision partner described that:  
 “The first thing you do is go into research mode, so try to find out as much information as 
you can and let people who do what they do and go from there.  I think both of us went into 
the research mode; just find out as much as we could.” (058DP1, 54 yo, female, patient 
with deferred DCP).  
  
 Another participant, a decision partner shared that  
“I think it depends on-- you do it case-by-case and depending on their health literacy on 
how much they can digest at a given time.” (076DP2, 35 yo, female, patient with deferred 
DCP). 
 
Theme 2. Getting the Most Insight about Clinical Trials 
 Regardless of the reported decision control preferences, in order to make decisions about 
clinical trial participation, patients and decision partners both discussed the value of getting as 
much insight as possible about clinical trials.  In order to optimize their knowledge about clinical 
trials, broaden their perspectives, and facilitate clinical trial decision making, participants 
reported learning from multiple sources, including consulting with different providers, social 
media and blogs, television, browsing different search engines, reading research articles, in 
addition to talking with family members, friends, and colleagues who had experience in research 
or healthcare systems in order to gain different perspectives and as much information as possible 
about clinical trials. One participant shared that:  
“I suppose I would probably talk to my oncologist, and I would probably talk to my friends 
or colleagues who are oncologists, if there was some question or concern I had….it’s good 
to have somebody who has that depth of understanding to be able to, you know, run by 
issues, and to kind of sort through what seems to be a reasonable path forward.”  (078P, 
49 yo, female, deferred DCP). 
 





“We would seek out the opinion of more than one professional.” (061DP1, 69 yo, male, 
patient with deferred DCP).  
 
Moreover, other participants verbalized a desire to be able to talk in-depth to individuals 
who may have the most insight about clinical trials such as research team members, patients who 
were enrolled or had participated in the specific clinical trial that they were considering or 
patients who have participated in clinical trials in the past, patients with a similar diagnosis, and 
their oncologist or the doctor who was leading the specific clinical trial.  
One patient stated:  
“I know with HIPAA laws, your doctor can’t say “Oh, here’s two people I’d like you’d to 
call and they’re participating and see what they think.”  I don’t know if that somehow a.. 
once-a-month support group that met somewhere where, if people had questions, they 
could come in and discuss type of thing.” (058P, 55 yo, male, deferred DCP) 
Another patient said:  
“I’d definitely like to know if somebody else has done them before, I mean because they 
are something that I feel like is not as tried and true, I guess I should say. So I’m open to 
them but I’m still very hesitant because I feel like it’s-- unless I know somebody who’s 
been through it and has come out okay <laughs> on the other side, it feels like it’s a little 
riskier. To have people who have been through them before is definitely a good thing. I 
know it’s helpful for me to know somebody who’s in my same situation, at least as far as 
my diagnosis goes, and I think if a clinical trial was to happen to be able to talk to 
somebody who’s maybe been through a similar trial.” (071P, 45 yo, female, deferred 
DCP) 
 
Individuals with a high DCP reported to not asking many, if at all, questions about clinical 
trials. Instead, they preferred to gather information on their own by reading about clinical trials, 
relying on their own perceptions and assumptions, or trusting the recommendation of either their 
primary care doctor or oncologist. Individuals with a deferred decision style reported that they 





members and multiple providers’ input. Here is one account from a decision partner about how 
they get the most insight during clinical trial decision-making if one was presented to his wife.  
“We ask a lot of questions. Yeah. We think about it a lot and ask questions and read 
about it and early on her brother was involved because he was actually involved in the 
research that came up with the drug that she’s using now, with the clinical trial with 
animals. He was very interested and gave us a lot of information.” (066DP1, 63yo, male, 
patient with deferred DCP) 
 
Theme 3.  Building Relationships…Trusting Someone in the Process 
When asked specifically about what comes to mind when they hear the term “clinical 
trials”, participants provided responses including: risky, experimental, unproven, an opportunity 
to receive new treatments, an avenue to pave the way for others to receive new therapies and to 
advance scientific knowledge. Since the risks and benefits of clinical trials are often unknown, 
participants discussed the importance of developing a trusting relationship with someone as they 
are deciding about clinical trial participation.  
Partnership and trust with provider.  Even though patients varied in their decision control 
preferences, all patients as well as many decision partners shared the importance of having a 
strong relationship with their oncologist or their primary care provider when making decisions 
about clinical trials.   
“I love my oncologist. I've been very, very happy with my doctor. But I think the more that 
the oncologists know, the front line, the better off. They're the ones who typically lead 
people. They're the ones you need to talk to.” (061P, 58yo, female, deferred DCP). 
 
“I’m in a good relationship with all of them, because I don’t know.” (063P, 70 yo, male, 
deferred DCP).   
 
“Any question that I do have, I put it to my oncology physician, my attending, and she’s 
been very helpful.” (070P, 65 yo, male, deferred DCP). 
 
 Network and access to people. Some participants trusted the input of family members 





process. For example, one patient said that since her brother went through a clinical trial and is 
now in remission, then she “has a lot of faith in a clinical trial.” (081P, 74 yo, female, deferred 
DCP). Additionally, for patients with decision partners, they described their relationships with 
decision partners as invaluable to the decision-making process. Those patients who reported a 
deferred decision style reported that the role of the decision partner included being an important 
advisor, supporting the patient’s decision-making and autonomy, being available for the patient, 
offering guidance and reassurance, and serving as a listener ear to discuss different options. 
Decision partners shared similar comments by describing their role as helping the patient 
consider the treatment options, weigh out the consequences of being in a clinical trial, and be 
able to provide an extra set of ears to hear the information that was being delivered by the health 
care team.  
One decision partner shared that:  
“Oh, everything gets bounced off of me. We both make the decision jointly.” (066DP1, 
63yo, male, patient with deferred DCP). 
 
 Whether patients had been offered or not offered a clinical trial, those with a deferred 
decision style acknowledged that it was important to talk about it with their decision partner to 
some extent. Some patients described decision partners as being a sounding board, meaning that 
they were someone that patients trusted and wanted to be a part of decision-making with them. 
One patient talked about the role of her husband: 
“Even factoring in genetics and everything else, there was still some concern on my part, 
and he was a good sounding board to have for that, but he’s the primary person that I’ve 
spoken to about it other than my doctors.” (071P, 45 yo, female, deferred DCP) 
 
This patient’s husband shared that:  
 
“I think it’s important to have someone else to be that sounding board.” (071DP1, 47 yo, 






Another patient also used the word “sounding board” to describe the role of her husband, who 
was her decision partner and had experience in health care: 
“He also understands a lot about drugs, he’s a good sounding board, and it’s good to have 
somebody who has that depth of understanding to be able to, you know, run by issues.” 
(078P, 49 yo, female, deferred DCP). 
 
 It was also important for participants to utilize their social networks and their access to 
certain people, such as researchers and physicians, in order to facilitate clinical trial decision-
making. In the interviews, social networks and access to certain people were often associated 
with the participants’ work or familial networks. One decision partner had a medical background 
and she described the important role of utilizing her networks when helping her friend in the 
clinical trial decision-making process:  
“But I do know that I can ask for help and I-- of course, I can access the health system 
where it’s very collaborative. So, I can always-- I always have colleagues.” (076DP2, 35 
yo, female, patient with deferred DCP). 
 
 Building a culture of research and seeking those with an invested interest. Others 
reported that access to research and clinical staff was important when making a clinical trial 
decision about clinical trial participation in order to build a culture of research where patients 
and decision partners can feel supported, have positive experiences with research and clinical 
trials, and can trust that researchers and providers who are conducting the clinical trials have an 
invested interest in the patients when asking them to consider clinical trial participation. With 
regards to building the culture of research, it was important to talk with members of the research 
team early on during the decision-making process. One decision partner shared that:  
“Communication at any time in any kind of study will go a long way.  Even if you were just 
scared about something, just to have somebody acknowledge that they heard you is huge.” 






Another participant shared a similar response:   
“Just whoever is involved with the trial...and maybe the doctor in charge of it.” (066DP1, 
68 yo, male, patient with deferred DCP). 
 
Another patient had a high DCP and did not identify a decision partner. He responded 
differently when asked about whether it was important to talk with the research team. He replied:  
“In all candidness no, because my thought is that, if they are the research team, then they 
have a vested interest in it. I would think that, if I needed medical advice per se, I would get 
that advice from a primary care physician.” (057P, 65 yo, male, high DCP).  
 
Theme 4. Realizing Readiness and Context 
 The decision-making process also involved meeting the patient where they are in their 
current emotional readiness, clinical situation, as well as health literacy and knowledge about 
clinical trials.  
Being emotionally ready. In the interviews, there was a growing consensus that there was 
no ideal or exact time to introduce clinical trials as a treatment option and it was important for 
decision partners and providers to meet and support the patient where they are both emotionally 
and clinically in the decision-making process. One decision partner gave insight about his friend: 
“She distances herself sometimes she don’t hear everything the doctor is saying and 
sometimes, you know, she could have questions because she distances herself from the 
situation.” (072DP1, 52 yo, male, patient with high DCP).  
 
 Another patient shared that:  
“I'm not even sure what clinical trials are. I'm not sure…Sometimes my thoughts and stuff 
is not that so I'm clear and stuff and so a lot of times and sometimes I'm not sure what 






Unique to the individual. Giving patients time to cope with the diagnosis prior to making a 
clinical trial decision was discussed most frequently among participants. Many participants 
explained that the process of clinical trial decision-making can be overwhelming when trying to 
cope with a cancer diagnosis:  
“I think at the first diagnosis it might be a little early <laughs>. Kind of get what-- kind of 
used to what's happening to them. I don't know other than just having the doctor aware that 
there are some out there that would be beneficial to their patient”. (066P, 63 yo, female, 
deferred DCP) 
 
Depends on cancer type and disease progression. Some noted that clinical trials should be 
viewed as a last resort treatment option and that it was important to consider the cancer type and 
disease progress when deciding about clinical trials.    
“I think it depends on what kind of cancer you have. It really depends. I think you definitely 
need to look into it when you've tried the normal things and they're not working anymore.” 
(061P, 58 yo, female, deferred DCP) 
 
Other participants expressed the benefit of learning about the possibility of a clinical trial early in 
the diagnosis in order to be adequately prepared to make a decision. 
“Well, I think that, once a person is diagnosed, I think that it's very important to reach 









Figure 1. Themes and subthemes from the qualitative interviews.  
 
Discussion 
There is an extensive body of literature describing the barriers and facilitators 
experienced by patients related to clinical trial participation (Bell & Balneaves, 2015). Most 
clinical trial participation research has focused on enrollment as the primary outcome rather than 
the process of decision making (Biedrzycki, 2010).  Moreover, prior research is limited in its 
understanding of patients’ perspectives of the decision-making processes surrounding clinical 
trial participation and the sociopolitical context in which these decisions are made (Bell & 
Balneaves, 2015). In particular, researchers have been slow to adopt a relational autonomy lens 
when exploring cancer patients’ clinical trial decisions despite growing recognition in the 
bioethics literature of the significance of social networks and sociopolitical influences on 
patients’ autonomy within general health care decision-making processes (Bell & Balneaves, 





researchers are aware of the potential for individuals to be unduly influenced by others (Bell & 
Balneaves, 2015), and such influences could include decision partners. Therefore, our 
exploration of the process of decision making about clinical trial participation among persons 
with varying decision control preferences presents an important opportunity to examine patients’ 
decision control preferences and potential influence on clinical trial decision-making.  
This study has highlighted the critical role of decision partners for adult cancer patients as 
they make clinical trial-related decisions, especially given that most of the individuals in our 
sample reported a deferred decision style (83%). Research on decision control preferences has 
repeatedly shown that a shared approach to control decision making in healthcare is preferred by 
the largest group of patients (Schuler et al., 2017).  The findings from this study suggest that as 
patients make clinical trial decisions, it is important to develop and maintain relationships with 
people they trust, evaluate their unique circumstances, have the freedom to choose and 
maintaining a sense of autonomy, and acquire as much insight as possible about clinical trials, 
even among patients with varying decision control preferences. Participants also shared that 
decision-making self-efficacy is needed in clinical trial decision-making due to its unknown 
outcomes. This trait could be demonstrated by either the patient or the decision partner. These 
findings are similar to other qualitative studies, where the level of trust patients had in their 
doctors’ recommendation regarding whether a trial would be an appropriate medical option for 
them was an important factor that predominantly influenced clinical trial decision making 
(Brown, Shuk, Leighl, Butow, Ostroff, Edgerson, & Tattersall, 2011).  Research has shown that 
physicians and their relationship with patients are important factors in patients’ decisions about 





Of note, half (50%, n=6) of the patients in the study were offered or received a delayed 
offer for a clinical trial.  This suggests that eligibility criteria and other factors remain a major 
barrier in being able to make decisions about clinical trial participation. Studies have described 
health care providers as “gatekeepers” to clinical trials and these individuals have a direct 
influence on the participation rate of their patients (Salman, Nguyen, Lee, & Cooksey-James, 
2016), which appears to be similar in our findings. Similar to other studies (Hill, Mogle, Wion, 
Kolanowski, Fick, Behrens, Muhall, & McDowell, 2017), we found that relationships with the 
research team also impacts a patient’s decision to participate in a clinical trial. Nonetheless, it 
was important for the participants to gather as much information and insight into clinical trials as 
possible before making a decision.  
The theme, realizing readiness and context, was described as an important aspect of the 
decision-making process. In short, clinical trial offers should include an understanding of the 
importance of emotional readiness and cancer type of the patient. Research has shown that the 
decision of selecting a specific cancer treatment is difficult and anxiety-producing, and the 
hardship is even greater when the options include clinical trials, as experimental treatments have 
no proven benefits (Wray, Stryker, Winer, Demetri, & Emmons, 2007), and decision made under 
the pressure of life-threatening disease by cancer patients may limit attention to and 
comprehension of consent materials (Wray, Stryker, Winder, Demetri, & Emmons, 2007; 
Huizinga, Sleijfer, van de Wiel, & van der Graaf, 1999).  
In the past, patients’ attitudes toward living with cancer have been shown to affect 
whether they can decide to accept or decline participation in cancer phase I clinical trials with or 
without hesitating or wavering (Kohara & Inoue, 2010). Additionally, patients’ attitudes toward 





barrier for patients and prevent them from participating in a clinical trial (Lee, Ow, Lie, & Dent, 
2016). In line with previous research, many of our participants described clinical trials as risky, 
unproven, and experimental, which impacted how they make decisions about clinical trial 
participation.  
Furthermore, the patients and decision partners had diverse experiences with cancer, 
clinical trials, health care systems, and came from different occupational and educational 
backgrounds. Thus, when clinical trials are offered, it is important to consider the context of that 
individual patient and communicate in a way that is well understood, allowing patients to make 
informed choices. Research suggest providing a question prompt list for patients as they have 
discussions about clinical trials (Brown et al., 2011) and evaluating their level of understanding 
about research (Joffe, Cook, Cleary, Clark, & Weeks, 2001).  These question prompt lists may 
help level the opportunities that patients have about getting insight and information about clinical 
trials by first knowing what questions to ask. 
Strengths and Limitations 
 There are some limitations that are inherent to this type of research. First, this study may 
present potential biases in the data in that those who participated in the interviews were limited 
to include participants who were already enrolled in the parent study who completed the Control 
Preferences Scale. Second, it is important to keep in mind that the study participants who 
consented had a desire or willingness to participate in the interviews, which may potentially lead 
to biases in the data. Those patients who refused to participate in the qualitative interviews (36%, 
n=7) may have reported similar or dissimilar views regarding clinical trial decision-making and 
the role of decision partners. Unfortunately, we were not able to gain further insight into why 





Third, there is potential for socially desirability bias, where participants may have 
answered questions in a manner that will be viewed favorably by others.  Fourth, it is important 
to recognize the demographic characteristics of the participants. We were limited to adult cancer 
patients living within one state in the southeastern part of the United States with selected types of 
cancer diagnoses based on the parent study. Furthermore, findings may be different for 
individuals who lived in other geographic regions and with other types of cancer diagnoses. 
Fifth, in the interviews, we asked participants to reflect on the sum of their experiences from 
initial diagnosis to past and current treatment to clinical trial treatment decision making. Since 
the majority of our patients were diagnosed within the last 2 years (67%), most of our patients 
and decision partners did not have difficult recalling information. However, when conducting 
qualitative interviews about past and present experiences, there is possibility of some recall 
biases in their responses.  Sixth, not all interviews were completed in the same manner, so this 
may have been both a limitation and a strength to elicit experiences and perspectives about 
clinical trials. Seventh, given the hypothetical nature of this study, some individuals were not 
offered a clinical trial during the initial clinic visit when baseline data was collected for the 
parent study, while others were offered a clinical trial. Nonetheless, findings from analyses can 
be useful in planning targeted outreach and education about clinical trials as well as to 
potentially improve recruitment approaches for clinical trial participation.  
 Despite these limitations, this research study has numerous strengths.  The dyadic 
approach of our research enhanced our ability to understand the role of decision partners in the 
clinical trial decision-making process and how their role may affect clinical trial participation. 
The perspectives of the decision partners help to contextualize and elaborate on the 





participation, such as sociodemographic factors including educational level, age, gender, and 
race.  Moreover, dyadic interviews allow for an interaction between participants in the interview 
and observations of how the comments of one participant draw forth responses from the other 
(Morgan, Ataie, Carder, & Hoffman, 2013). This kind of interaction facilitated the exchange of 
stories, which were particularly valuable as qualitative data (Morgan, Ataie, Carder, & Hoffman, 
2013). In addition, the qualitative interviews explored a broad range of topics including 
preferences to involve others in decision-making and perceptions about the word clinical trials.  
Furthermore, the sample included a nearly equal number of males and females for both patients 
and decision partners, a fairly broad range of cancer types among patients, and a racially diverse 
sample of individuals that reflected the makeup of the geographic region of the state where the 
study was conducted. Larger studies that include other diverse racial and ethnic groups will be 
useful to fully explore clinical trial decision-making across individuals who vary by decisional 
control preferences and determine their different needs for decision partner involvement.  
Conclusions 
Future research about clinical trial decision-making and the role of decision partners is 
essential to the development of clinical trial recruitment and retention, especially considering the 
social context in which patients reside in while making these decisions. The previous experiences 
that decision partners, family members, and friends have with regards to clinical trials may 
influence how patients make decisions about participation in important ways.  Future research is 
required to further examine the provider-patient relationship and how clinical or research 
interactions also involve decision partners. Additionally, whether or not patients enroll in a 
clinical trial, it is important to understand and support their decision-making processes and 





control preferences for decision partner involvement being evaluated early at the time of 
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CHAPTER VI: Conclusions and Implications 
Summary and Future Research 
There is a growing body of literature related to cancer treatment decision-making, 
globally, as well as specific factors that impact cancer clinical trial participation. This 
dissertation study is among the first to examine patients’ decision control preferences for 
decision partner involvement and the role of decision partners in clinical trial decision-making 
for adult cancer patients using quantitative and qualitative data sources in order to obtain 
multiple perspectives and a fuller understanding of their role.  
 In the quantitative arm of the dissertation study, we found that 73% (n=19) reported a 
deferred decision style.  In the qualitative arm, most patients (83%, n=10) identified at least one 
decision partner, but some patients did not (17%, n=2). Follow up studies should investigate 
reasons why some patients do not identify a decision partner and focus on developing ways to 
support their decision making. Research is also needed to understand why patients choose certain 
friends or family as their decision partners, and whether decision partner choice alters based on 
the type of decision or health context. Another area of future research should examine whether 
involvement of decision partners is correlated with more positive patient health outcomes and 
improved patients’ satisfaction with care, especially with our findings indicating that patients 
most often prefer a deferred decision style with decision partner involvement.  
Moreover, studies are needed to design and test psychometrically sound instruments to 
capture the latent variables that are associated with decision-making, knowledge, attitudes, and 
beliefs about clinical trial participation, and accurately measure health literacy about clinical 
trials. In the larger sample of participants who were not offered or received a delayed offer, we 





clinical trials, compared to those who were actually offered (p=0.566). Given this difference in 
p-values, future work is needed to potential provider bias and whether or not patients were not 
offered due to physicians’ perceptions and assumptions about a patient’s knowledge, attitudes, 
and beliefs or for clinical ineligibility.  Particularly, with the increasing numbers of studies in 
research ethics and a need to improve recruitment of research subjects, the ability to measure 
attitudes towards biomedical research has become important (Rubright, Cary, Karlawish, & Kim, 
2011).  With smaller sample of participants who were actually offered a clinical trial (in spite of 
all participants being screened as having at least one available clinical trial) limited power to 
detect statistically significant associations among variables, but we did recognize trends and 
patterns among certain sociodemographic variables such as gender, cancer type, and knowledge, 
attitudes, and beliefs about clinical trials, and clinical trial participation. Future work should also 
focus on creating and implementing conceptual frameworks that take into account patients’ 
decisional control preferences and show how these preferences fit into decision-making, plans of 
care, and patient outcomes.   
Research is also needed to develop and evaluate multi-faceted and multi-leveled 
interventions that aim to integrate decision partners more fully into the clinical trial decision-
making process with health care teams.  Our findings indicated that relationships were critically 
important in decision making and decision partners are often described as people that patients 
trust. We also learned from many interviews that patients also trust providers’ input with regards 
to clinical trial decision making. When decision partners, providers, and patients work together 
in clinical trial decision making, there is an opportunity for multiple perspectives to be shared 
that impact decision making. Furthermore, decision partners have the potential to help bridge 





about a patient’s personal, social, and community contexts as patients navigate within a health 
care system. In the interviews, the majority of the decision partners shared their experiences with 
research and clinical trials, working in health care, caring for a sick family member, had a 
background in public health, or held leadership positions in their career that led to them being 
strong patient advocates and resourceful with gathering information.  
Future studies may also focus on better understanding the impact that a cancer patient’s 
clinical trial participation has on the decision partner, the family, and within the workplace 
setting if the cancer patient is still working full-time while enrolled in a clinical trial. With the 
incorporation of stated-preference methods, researchers will be able to understand valuation and 
prioritization of key stakeholders in decision making, including patients, decision partners, 
employers, providers, insurance companies, and family members.  
Conclusions and Implications 
It is important to recognize that there are certain populations that continue to be 
vulnerable across many clinical contexts, including clinical trial decision making. Disparities 
continue to exist in cancer health outcomes. Furthermore, the lack of diversity in clinical trials 
can greatly compromise the outcomes of the trials since cancer varies greatly among gender, 
races, and cultures (Salman, Nguyen, Lee, & Cooksey-James, 2016), and this lack of diversity in 
clinical trials slows our progress in reducing cancer health disparities. Furthermore, the accrual 
and retention rates remain significantly lower in the adult cancer patients compared to pediatrics. 
Our study sample had a median age of 60.5 years.  Within this sample, we learned that 75% 
(n=61) of the individuals were either not offered or received a delayed offer regarding a clinical 
trial. This supports existing literature that older adults remain underrepresented in cancer clinical 





Reynier, Bechlian, Vey, & Chabbannon, 2014). Physicians are less likely to discuss this option 
with them (Mancini, Jansen, Julian-Reynier, Bechlian, Vey, & Chabbannon, 2014; Javid, Unger, 
Gralow, 2012), and older adults have been found to prefer a passive decision making role with 
their physicians (Lechner, Herzog, Boehlen, Maatouk, Saum, Brenner, & Wild, 2016). 
Therefore, it is important for decision partners to be present to help advocate for such 
opportunities, especially if these decision partners bring knowledge about research and health 
care. Also, patients with lower health literacy levels are likely to prefer a passive role in 
decision-making (Mancini et al., 2014), making decision partners even more pivotal in the 
decision-making process.  
Furthermore, participants in this study were receiving care from an outpatient setting, 
which is an underserved population with regards to understanding their supportive care needs 
within the health care system and having access to resources if they were otherwise inpatient to 
help them make informed decisions.  Research have suggested that one in two outpatient cancer 
patients have not used any of the existing and available supportive and palliative care services 
since their diagnosis (Kumar, Casarett, Corcoran, Desai, Li, Chen, Langer, & Mao, 2012), and 
those who utilize these services were more likely to have a higher level of education (Adler & 
Newman, 2002; Kumar et al., 2016).  For these outpatient cancer patients, as was in our sample, 
it is critically important to have decision partners to help in decision making, considering that 
they often live close to the patients or in frequent communication with them.  
Geographic proximity is also another important in clinical trial decision making.  Patients 
who do not live close to the clinic or near a health care facility that conducts clinical trials could 
be greatly disadvantaged.  Most cancer clinical trials are only available at academic and cancer 





patients who live in and receive treatment in their ethnic community (Salman, Nguyen, Lee, & 
Cooksey-James, 2016; Lin, Finlay, Tu, & Gany, 2005). For patients who do not drive long 
distances, decision partners may be essential in influencing patients’ decisions about clinical trial 
participation if they are willing to help with getting patients to appointments and help the patient 
meet other clinical trial commitments.  
As we learned from this study, many patients with greater knowledge and more positive 
attitudes and beliefs about clinical trials either had prior experience with clinical trials or knew 
someone in their social network who had had a positive experience participating in clinical trials. 
Therefore, it is critical to learn more about who these decision partners are who are involved in 
decision making and understand their backgrounds and familiarity with clinical trials as they are 
influential in aiding in impeding clinical trial participation.  
Finally, we need to look beyond oncology populations and investigate the role of decision 
partners in other illnesses, diseases, and types of decisions. The highly complex, dynamic and 
interrelated character of many family decisions suggests that decision-making processes could be 
studied more effectively across decisions, rather than in relation to any given decision 
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Appendix C: Interview Guide 
 
        Participant Interview Guide 










Thank you for agreeing to participate.  I am interviewing you to learn about your experience in making 
health-related decisions and in working with EMPaCT patient navigators.   
 
This interview will last no more than one hour. By the end of this interview, I would like to have an 
overall picture of your experience. Do you have any questions before we begin? 
 
Part 1 – Interview Questions for Patient Participant 
 
BACKGROUND QUESTIONS:  
I would like to ask you a few questions before we get started to learn a little bit more about you.   
 
1. Why don’t we talk about the time you were diagnosed with cancer? 
PROBE: How were you feeling? How were you processing it?  
 
2. Related to your cancer care, how do you like to include people (family, friends, doctor, 
nurses) in health-related decisions?  
 
3. One of the reasons that I contacted you for an interview is to understand how you made 
a decision about whether or not to participate in research. In general, what are your 
ideas about participating in research?  
PROBES:  
a. What had you heard about research studies and clinical trials before one was offered to you as 
a treatment option? 
b.  When you hear the term clinical trial, what comes to mind?  
c. What do you think about when you are invited to participate in a clinical trial?   
 
4. Were you offered other clinical trials before this one, and did you decide to participate?  
a. IF NO:  clarify answer, e.g. not offered other clinical trials? Or no to participation? 




Date: ____________  Participant ID or Pseudonym: _______________ 
 





Please keep in mind that whenever I say “clinical trial”, I am referring to the clinical trial in which 




5. What motivated you to participate [or not participate] in this clinical trial? 
PROBES:  
a. Was the clinical trial your only treatment option? 
b. Who did you discuss clinical trial participation with?  
i. Your doctor?  Your nurse? What did he/she tell you? 
ii. Family and/or friends who serve as a decision partner? What did they tell you? 
c. What role did [DECISION PARTNER NAME] play in helping you reach a decision about 
participating in the clinical trial? 
d. What role did [PATIENT NAVIGATOR NAME] play in helping you make the decision to 
participate in the clinical trial? 
e. What are the benefits of including your decision partner in clinical trial decisions? 
f. What are the challenges in including your decision partner in clinical trial decisions? 
 
6. Did you have any concerns about taking part in THIS clinical trial? 
a. IF YES: What were the main concerns you had about taking part in this clinical trial? 
PROBE: What did you anticipate when you were thinking about enrolling in this study? 
PROBE: For example, related to clinical trial requirements, your family, how the research is done, 
the drug itself, other treatment related concerns  
 
b. In the case of your concerns about [FILL IN CONCERN MENTIONED ABOVE], were these 
concerns addressed?  By whom? 
PROBE: How did you overcome these concerns? During recruitment/screening process? After 
enrollment?   
PROBE: How did others help you to overcome these concerns?   
i. Family/friends? 
ii. Doctors? 
iii. Nurses?     
iv. If doctors or nurses not mentioned above: Did you discuss your concerns with your 
doctor or nurse?   
 
Experience with Patient Navigator 
 
7. How did you first come in contact with your patient navigator, [PATIENT 
NAVIGATOR NAME]?  
 
PROBE:  Had your doctor or nurse told you that a patient navigator would be contacting you? 
a. Think back to the time when [PATIENT NAVIGATOR NAME] first called you.  Do you 
remember what you thought or how you felt about her contacting you? 
PROBE:  Was the call welcomed, or did you think the call was intrusive? In what way was it 
[welcomed/ intrusive]? 
a. What were your thoughts about being contacted by someone you did not know who wanted to 
discuss barriers you might have to cancer treatment or participation in a clinical trial?  
b. What questions did [PATIENT NAVIGATOR NAME] discuss during that first call? 






8. Please tell me about your experience working with the patient navigator [PATIENT 
NAVIGATOR NAME].  
PROBES:  
a. How would you describe the interactions and your overall relationship with the navigator? 
OR  
b. Please describe your view of the navigator’s role in working with you. 
c.  How did the navigator assist you in understanding what was required of you as a participant 
in the trial as you were making a decision whether or not to participate?   
d. What did the navigator help you with?  
e. To you, what was the most important part of working with [PATIENT NAVIGATOR NAME]?  
f. Was there anything about [PATIENT NAVIGATOR NAME] that made you feel confident that 
she could help you?  
g. What things were you less confident about [PATIENT NAVIGATOR NAME] helping you 
with? 
h. Was there anything about [PATIENT NAVIGATOR NAME] that made you feel 
uncomfortable? 
i. Did [PATIENT NAVIGATOR NAME] encourage you to discuss your concerns with your 
doctor or nurse, give you reminder calls, meet you in the clinic etc? 
j. Did [PATIENT NAVIGATOR NAME] give you medical advice for example, recommending 
over the counter drugs? 
i. IF YES: What was the advice? 
 
9.  What was your impression about how [PATIENT NAVIGATOR NAME] worked with 
the rest of the clinic team, for example with the clinic staff, the nurses, or the doctors?   
a. To you, did it seem like she was part of that team?  Why or why not? 
PROBE: How is your communication with the patient navigator different than your 
communication with the other research staff such as nurses or doctors?   
 
Part 2 – Interview Questions for Decision Partner 
 
1. What is it like being invited with the [PATIENT’S PSEUDONYM] as they make health-
related decisions?  
 
2. Could you tell me about how you were involved in the decision related to whether or not 
[PATIENT’S PSEUDONYM] participated in research studies or clinical trials?   
 
3. What has helped you as you participate in the decision-making process? 
 
4. What are some of the challenges in participating in the decision-making process? 
 




1. What would make the process of deciding whether or not to take part in a clinical trial 






2. What things can we do to make the patient navigator program better for this clinical 
trial?  
PROBES:  
b. What were you satisfied with? 
c. How the navigator got in touch with you the first time (and afterwards)?  
d. Information that the navigator shared and discussed with you?   
e. The frequency/mode/duration of interaction?  
 
3. For those considering participation in this clinical trial, would you recommend that 
other participants work with a patient navigator? A decision partner? Why or why 
not? 
 
4. Any final thoughts about the patient navigator program or your experience with your 












Appendix D: Survey Instruments Table 









Measurement  # of 
Items 









Control Preferences Scale (CPS)  
Slight modifications were made to 
this scale to assess participation 
preference for treatment decisions 
with providers. The CPS consists of 
five cards that each portrays a 
different role in treatment decision-
making using a statement. These 
roles range from the individual 
making the treatment decisions, 
through the individual making the 
decisions jointly with the decision 
partner and/or physicians, to the 
decision partner and/or physician 
making the decisions 
 
2 One of five 










has been modified for 










Clinical Trial Knowledge Assessment  
To measure understanding of key 










Appendix E.  Clinical Trial Knowledge, Beliefs, and Attitudes Assessment 
 
Clinical Trial Knowledge, Beliefs, and Attitudes Assessment 
 
People participate in clinical trials for a variety of reasons. Rate your agreement/disagreement 
with each of the following statements concerning participation in a clinical research trial:  
 




Agree Neutral Disagree Strongly 
Disagree 
1. The information gained 
from clinical trials may help 
a friend or family member 
diagnosed with my same 
illness in the future.  
 
     
2. Clinical trials often offer 
the best treatment available.  
 
     
3. Most of the current 
treatments for cancer are 
based on evidence from 
previous clinical trials.  
 
     
4. I would not participate in a 
clinical trial due to potential 
side effects.  
 
     
5. All possible measures to 
protect my safety and privacy 




     
6. If most patients refused to 
take part in clinical trials, 
important developments in 
medicine would be seriously 
delayed.  
 
     
7. It is important for me to be 
compensated financially for 
my participation in a clinical 
trial.  
 
     
8. Without results from 
clinical trials, doctors would 
be less able to select the best 
treatment for my age, race, 
and ethnicity.  
 




































9. I think all patients who are 
eligible should be asked to 
take part in clinical trials.  
 
     
10. I am worried that taking 
part in a clinical trial will 
inconvenience me.  
 
     
11. I would only take part in 
a clinical trial if I thought 
that my own health would 
benefit. 
 
     
12. I think I would find being 
in a clinical trial frightening.  
 
     
13. I trust my doctor and 
would participate in a clinical 
trial if she/he recommended I 
do so.  
 
     
14. Participating in clinical 
trials may provide new, and 
often expensive, treatment to 
patients at reduced costs.  
 
     
15. I know someone who has 
participated in a clinical trial. 
  
     
16. I have participated in a 
clinical trial in the past.  
 
     
17. I believe clinical research 
trials are important.  
 
     
18. The results of a clinical 
trial that I participated in may 
help others in the future with 
my same diagnosis.  
 
     













     
     
    
    
     
 
 























Control Preferences Scale  
 
The role you want other people to play in your health care treatment decisions is important. This questionnaire looks 
at the level of control in which you want family members and/or friends to assume when decisions are being made 
about your cancer-related treatment.  Tell us how you would like treatment decisions to be made by circling one text 












Family and Friends 
In making decisions about your health care now, how do you weigh the input of your doctor and the input of your 
loved ones? Circle one. 
1 = My doctor's input weighs most heavily. 
2 = My family/friends’ input weighs most heavily. 











will receive.  
I prefer to make the 
final decision about 
which treatment I 
will receive after 
seriously 
considering the 
opinion of my 
family /friends.   
I prefer that my 




treatment I will 
receive.  
I prefer that my 
family/friends 
make the final 
decision about 
which treatment 











to my family 
/friends.  
1 3 4 5 2 
  
Date:  ________________________              Version 1 Pre: ___________________ 





Appendix G.  Inclusion/Exclusion Criteria for Quantitative Study 
 
Quantitative Study Inclusion/Exclusion Criteria (Same as Parent Study) 
Inclusion Criteria Exclusion Criteria 
• Must be over 18 years  
• Patient has a primary solid tumor cancer 
diagnosis [initial focus:  Breast, Colon, 
Lung, Pancreas, Prostate, Multiple 
Myeloma, or Head and Neck]  
• Patient must have an available therapeutic 
clinical trial, identified through pre-
screening/medical record review  
• Resident of Maryland 
• Able to read and write in English*  
 
• Do not have an available 




• Not a resident of Maryland 
*added to dissertation study inclusion criteria 
 
 
Appendix H.  Inclusion/Exclusion Criteria for Qualitative Study 
 
Qualitative Study Inclusion/Exclusion Criteria 
Adult Cancer Patient Decision Partner 
• Must be 18 years or older 
• Patient has a primary solid tumor 
cancer diagnosis [initial focus:  
Breast, Colon, Lung, Pancreas, 
Prostate, Multiple Myeloma, or 
Head and Neck]  
• Patient must have an available 
therapeutic trial, identified through 
pre-screening/medical record review  
• Resident of Maryland 
• Patient, if applicable based on their 
scores for the Control Preferences 
Scale, can identify a decision 
partner.  
• Must have completed Control 
Preferences Scale 
• Able to read, write, and understand 
in English  
 
• Must be 18 years or older 
• Able to read and write in English 
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